valproic acid has been researched along with Acute Disease in 249 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Acute Disease: Disease having a short and relatively severe course.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Topiramate, a structurally novel anticonvulsant, is being evaluated for other neurological conditions such as migraine, neuropathic pain, and essential tremor, and also for psychiatric conditions such as bipolar disorder, bulimia, post-traumatic stress disorder, and schizoaffective disorder, in addition to obesity." | 10.19 | The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. ( Chengappa, KN; Gershon, S; Levine, J, 2001) |
| "To evaluate the efficacy and tolerability of the treatment with valproic acid (VPA) in patients with status epilepticus (SE) or acute repetitive seizures (ARS) comparing it with phenytoin (PHT) treatment." | 9.13 | Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. ( Dabby, R; Gilad, R; Izkovitz, N; Lampl, Y; Rapoport, A; Sadeh, M; Weller, B, 2008) |
| "Oxcarbazepine, a keto derivative of the 'mood stabiliser' carbamazepine, may have efficacy in the treatment of acute episodes of bipolar disorder." | 8.87 | Oxcarbazepine for acute affective episodes in bipolar disorder. ( Geddes, J; Macritchie, K; Vasudev, A; Vasudev, K; Watson, S; Young, AH, 2011) |
| "Valproic acid (VPA) is a commonly prescribed medication approved for use in the United States for epilepsy, migraine, and bipolar disorder." | 8.82 | Acute pancreatitis in children from Valproic acid: case series and review. ( Feldman-Winter, LB; Goldfarb, O; Grauso-Eby, NL; McAbee, GN, 2003) |
| "A 12-year-old boy developed pancreatitis, complicated by a pancreatic pseudocyst, as an adverse reaction to valproic acid (VPA) treatment for epilepsy." | 8.82 | Pancreatitis, complicated by a pancreatic pseudocyst associated with the use of valproic acid. ( Houben, ML; Stroink, H; van Dijken, PJ; Wilting, I, 2005) |
| "We describe a case of a 31-year-old woman with cerebral palsy who developed fatal acute hemorrhagic pancreatitis while being treated with valproic acid to control her seizure activity." | 8.79 | Fatal acute pancreatitis caused by valproic acid. ( Evans, RJ; Jordan, J; Krolikowski, FJ; Miranda, RN, 1995) |
| "Acute pancreatitis is a rare, albeit severe, secondary effect of valproic acid which is probably due to an idiosyncratic reaction." | 8.79 | [Acute pancreatitis caused by valproic acid: apropos a case]. ( Bahamonde Carrasco, A; Morán Blanco, A; Olcoz Goñi, JL, 1996) |
| "We reported a case of acute pancreatitis occurring during administration of valproic acid for epilepsy." | 8.78 | [A case of acute pancreatitis during administration of valproic acid]. ( Ito, S; Kobayashi, K; Kuniya, T; Mimasu, S; Momota, T, 1993) |
| "An 11 year-old epileptic boy, treated with valproic acid developed after 11 months on therapy a severe acute pancreatitis." | 8.78 | [Acute pancreatitis and valproic acid]. ( Bovier Lapierre, M; Jalaguier, E; Kayemba Kay's Kabangu, S, 1991) |
| "Valproic acid (VPA) is a relatively safe drug widely used for the treatment of epileptic seizures and mania in bipolar disorder, as well as the prevention of migraine headaches." | 8.31 | Acute pancreatitis during valproic acid administration in a patient with vascular dementia, epileptic seizures, and psychiatric symptoms: a case report. ( Harada, M; Hashimoto, R; Igata, R; Ikenouchi, A; Isomoto, N; Konishi, Y; Okamoto, N; Shinkai, T; Yanaga, M; Yoshimura, R, 2023) |
| " Divalproex loading was as well tolerated or better tolerated than the other active treatments as measured by adverse events and changes in laboratory parameters." | 7.80 | The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. ( Baker, JD; Hirschfeld, RM; Sommerville, KW; Tracy, K; Wozniak, P, 2003) |
| "Drug-induced acute pancreatitis is a rare condition in childhood, and information about the incidence of valproic acid-induced acute pancreatitis in the pediatric population is scarce." | 7.79 | Valproic acid-induced pancreatitis in a 15-year-old boy with juvenile myoclonic epilepsy. ( Talvik, I; Talvik, T; Uibo, O; Veri, K, 2013) |
| "To report a probable interaction between meropenem and valproic acid that resulted in the development of epileptic seizures." | 7.73 | Acute seizures due to a probable interaction between valproic acid and meropenem. ( Borrás-Blasco, J; Coves-Orts, FJ; Murcia-López, A; Navarro-Ruiz, A; Palacios-Ortega, F, 2005) |
| "A nondiabetic young male patient in hypomanic phase of bipolar disorder on maintenance treatment with sodium valproate, developed transient episode of acute pancreatitis and diabetic ketoacidosis after addition of chlorpromazine and halopridol." | 7.72 | Acute pancreatitis and diabetic ketoacidosis in non-diabetic person while on treatment with sodium valproate, chlorpromazine and haloperidol. ( Gupta, SB; Laghate, VD, 2004) |
| "A 47-year-old man suffering from a bipolar disorder and intermittent myoglobinuria presented with acute rhabdomyolysis with renal failure after starting therapy with valproic acid." | 7.71 | Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. ( Glocker, FX; Jaksch, M; Ketelsen, UP; Kottlors, M; Lücking, CH; Weiner, S, 2001) |
| "The development of acute pancreatitis in an 8-year-old boy being treated with valproic acid for simple absence spells is documented." | 7.66 | Pancreatitis associated with valproic acid therapy. ( Batalden, PB; Cloyd, J; Van Dyne, BJ, 1979) |
| "Valproic acid (VPA) is an antiepileptic drug that is now used for a variety of neurological and psychiatric indications." | 6.45 | Extracorporeal elimination in acute valproic acid poisoning. ( Thanacoody, RH, 2009) |
| "Lamotrigine has emerged as a first line treatment for bipolar depression, which is an area of weakness for other mood stabilizers." | 6.42 | Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders. ( Goodwin, FK; Lieberman, DZ, 2004) |
| "Topiramate, a structurally novel anticonvulsant, is being evaluated for other neurological conditions such as migraine, neuropathic pain, and essential tremor, and also for psychiatric conditions such as bipolar disorder, bulimia, post-traumatic stress disorder, and schizoaffective disorder, in addition to obesity." | 6.19 | The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder. ( Chengappa, KN; Gershon, S; Levine, J, 2001) |
| "Valproic acid (VPA) has shown potent anti-inflammatory effect and attenuates acute lung injury." | 5.48 | Valproic acid attenuates the risk of acute respiratory failure in patients with subarachnoid hemorrhage. ( Chien, WC; Chu, SJ; Chung, CH; Chung, TT; Liao, WI; Tsai, SH; Wang, JC, 2018) |
| "Acute pancreatitis is rarely seen in children, and it is often drug induced." | 5.35 | Acute hemorrhagic pancreatitis due to the use of valproic acid in a child. ( Köse, G; Ozaydin, E; Yükselgüngör, H, 2008) |
| "Ertapenem was discontinued, and his divalproex sodium dosage was increased further." | 5.34 | Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. ( Lunde, JL; Nelson, RE; Storandt, HF, 2007) |
| "Valproic acid has been previously associated with hematologic toxicity, including a reversible myelodysplasia-like syndrome without chromosomal abnormalities." | 5.33 | Acute leukemia associated with valproic acid treatment: a novel mechanism for leukemogenesis? ( Bair, AK; Coyle, TE; Mehdi, S; Stein, C; Vajpayee, N; Wright, J, 2005) |
| "We report a patient with focal epilepsy and latent hereditary coproporphyria who had exacerbation of clinical symptoms of porphyria under treatment with valproate and primidone and was then treated with levetiracetam without exacerbation of clinically latent porphyria." | 5.32 | Levetiracetam in focal epilepsy and hepatic porphyria: a case report. ( Meencke, HJ; Paul, F, 2004) |
| "Patients presenting with moderate to severe intensity migraine without aura were randomized to receive either 400 mg of iVPA or 10 mg intramuscular metoclopramide + 6 mg SQ sumatriptan (30 patients in each study arm)." | 5.17 | A randomized open-label study of sodium valproate vs sumatriptan and metoclopramide for prolonged migraine headache. ( Bakhshayesh, B; Hatamian, H; Hossieninezhad, M; Rezania, K; Seyed Saadat, SM, 2013) |
| "To evaluate the efficacy and tolerability of the treatment with valproic acid (VPA) in patients with status epilepticus (SE) or acute repetitive seizures (ARS) comparing it with phenytoin (PHT) treatment." | 5.13 | Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin. ( Dabby, R; Gilad, R; Izkovitz, N; Lampl, Y; Rapoport, A; Sadeh, M; Weller, B, 2008) |
| "This study examined direct treatment costs based on medication and service use data collected in a 47-week multi-center, double-blind, randomized clinical trial of olanzapine versus divalproex for patients with bipolar disorder and and experiencing acute mania." | 5.11 | Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial. ( Baker, RW; Lage, MJ; Shi, L; Tohen, M; Tunis, SL; Zhao, Z; Zhu, B, 2005) |
| "Comparison of the change in median VAS scores over 60 minutes revealed that sodium valproate was significantly less effective than prochlorperazine in reducing pain or nausea (P <." | 5.10 | Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial. ( French, T; Miller, S; Riffenburgh, RH; Tanen, DA, 2003) |
| "This 47-week, randomized, double-blind study compared flexibly dosed olanzapine (5-20 mg/day) to divalproex (500-2500 mg/day) for manic or mixed episodes of bipolar disorder (N=251)." | 5.10 | Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. ( Altshuler, L; Baker, RW; Brown, E; Frye, M; Ketter, TA; Risser, RC; Schuh, LM; Suppes, T; Tohen, M; Zajecka, J; Zarate, CA, 2003) |
| "This 3-week randomized, double-blind, placebo-controlled study included 156 bipolar disorder patients with a current manic or mixed episode who received a mood stabilizer (lithium or divalproex) and placebo, risperidone, or haloperidol." | 5.10 | Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. ( Bowden, CL; Ghaemi, SN; Grossman, F; Okamoto, A; Sachs, GS, 2002) |
| "After a < or = 1-day screening period, 36 consecutive hospitalized patients with bipolar disorder, manic or mixed phase and with psychotic features, were randomly assigned to receive either divalproex 20 mg/kg/day or haloperidol 0." | 5.08 | A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania. ( Bennett, JA; Keck, PE; McElroy, SL; Stanton, SP; Strakowski, SM; Tugrul, KC, 1996) |
| "Nineteen patients with bipolar disorder, manic phase, received divalproex sodium 20 mg/kg/day in divided dosages for 5 days, without other psychotropic agents except lorazepam up to 4 mg/day." | 5.07 | Valproate oral loading in the treatment of acute mania. ( Bennett, JA; Keck, PE; McElroy, SL; Tugrul, KC, 1993) |
| "Oxcarbazepine, a keto derivative of the 'mood stabiliser' carbamazepine, may have efficacy in the treatment of acute episodes of bipolar disorder." | 4.87 | Oxcarbazepine for acute affective episodes in bipolar disorder. ( Geddes, J; Macritchie, K; Vasudev, A; Vasudev, K; Watson, S; Young, AH, 2011) |
| "A MEDLINE (1967-June 2007) and bibliographic search of the English-language literature was conducted using the search terms valproic acid and migraine disorders." | 4.84 | Use of intravenous valproic acid for acute migraine. ( Foraker, KC; Frazee, LA, 2008) |
| "Valproic acid (VPA) is a commonly prescribed medication approved for use in the United States for epilepsy, migraine, and bipolar disorder." | 4.82 | Acute pancreatitis in children from Valproic acid: case series and review. ( Feldman-Winter, LB; Goldfarb, O; Grauso-Eby, NL; McAbee, GN, 2003) |
| "Although monotherapy with lithium or divalproex is the recommended initial therapy for bipolar disorder, these agents are associated with prolonged favorable outcomes in only 30% of patients." | 4.82 | Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder. ( Bowden, CL, 2005) |
| "A 12-year-old boy developed pancreatitis, complicated by a pancreatic pseudocyst, as an adverse reaction to valproic acid (VPA) treatment for epilepsy." | 4.82 | Pancreatitis, complicated by a pancreatic pseudocyst associated with the use of valproic acid. ( Houben, ML; Stroink, H; van Dijken, PJ; Wilting, I, 2005) |
| "Mood-stabilizing drugs including lithium, anticonvulsants, and antipsychotics have established effects in the management of bipolar disorder, especially in mania." | 4.80 | Mood-stabilizing drugs in depression. ( Shelton, RC, 1999) |
| "We describe a case of a 31-year-old woman with cerebral palsy who developed fatal acute hemorrhagic pancreatitis while being treated with valproic acid to control her seizure activity." | 4.79 | Fatal acute pancreatitis caused by valproic acid. ( Evans, RJ; Jordan, J; Krolikowski, FJ; Miranda, RN, 1995) |
| "Acute pancreatitis is a rare, albeit severe, secondary effect of valproic acid which is probably due to an idiosyncratic reaction." | 4.79 | [Acute pancreatitis caused by valproic acid: apropos a case]. ( Bahamonde Carrasco, A; Morán Blanco, A; Olcoz Goñi, JL, 1996) |
| "We reported a case of acute pancreatitis occurring during administration of valproic acid for epilepsy." | 4.78 | [A case of acute pancreatitis during administration of valproic acid]. ( Ito, S; Kobayashi, K; Kuniya, T; Mimasu, S; Momota, T, 1993) |
| "An 11 year-old epileptic boy, treated with valproic acid developed after 11 months on therapy a severe acute pancreatitis." | 4.78 | [Acute pancreatitis and valproic acid]. ( Bovier Lapierre, M; Jalaguier, E; Kayemba Kay's Kabangu, S, 1991) |
| "Valproic acid (VPA) is a relatively safe drug widely used for the treatment of epileptic seizures and mania in bipolar disorder, as well as the prevention of migraine headaches." | 4.31 | Acute pancreatitis during valproic acid administration in a patient with vascular dementia, epileptic seizures, and psychiatric symptoms: a case report. ( Harada, M; Hashimoto, R; Igata, R; Ikenouchi, A; Isomoto, N; Konishi, Y; Okamoto, N; Shinkai, T; Yanaga, M; Yoshimura, R, 2023) |
| " Divalproex loading was as well tolerated or better tolerated than the other active treatments as measured by adverse events and changes in laboratory parameters." | 3.80 | The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder. ( Baker, JD; Hirschfeld, RM; Sommerville, KW; Tracy, K; Wozniak, P, 2003) |
| "Drug-induced acute pancreatitis is a rare condition in childhood, and information about the incidence of valproic acid-induced acute pancreatitis in the pediatric population is scarce." | 3.79 | Valproic acid-induced pancreatitis in a 15-year-old boy with juvenile myoclonic epilepsy. ( Talvik, I; Talvik, T; Uibo, O; Veri, K, 2013) |
| "Our study underscores the importance of considering drugs as a cause and a contributor to pancreatitis in children, particularly valproic acid in young children." | 3.77 | Novel characterization of drug-associated pancreatitis in children. ( Bai, HX; Bhandari, V; Husain, SZ; Latif, SU; Ma, MH; Orabi, AI; Park, A, 2011) |
| " The anticonvulsant activity of F1,6BP was determined in rat models of acute seizures induced by pilocarpine, kainic acid, or pentylenetetrazole." | 3.74 | Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats. ( Khan, FA; Lian, XY; Stringer, JL, 2007) |
| "To report a probable interaction between meropenem and valproic acid that resulted in the development of epileptic seizures." | 3.73 | Acute seizures due to a probable interaction between valproic acid and meropenem. ( Borrás-Blasco, J; Coves-Orts, FJ; Murcia-López, A; Navarro-Ruiz, A; Palacios-Ortega, F, 2005) |
| "A nondiabetic young male patient in hypomanic phase of bipolar disorder on maintenance treatment with sodium valproate, developed transient episode of acute pancreatitis and diabetic ketoacidosis after addition of chlorpromazine and halopridol." | 3.72 | Acute pancreatitis and diabetic ketoacidosis in non-diabetic person while on treatment with sodium valproate, chlorpromazine and haloperidol. ( Gupta, SB; Laghate, VD, 2004) |
| "A 47-year-old man suffering from a bipolar disorder and intermittent myoglobinuria presented with acute rhabdomyolysis with renal failure after starting therapy with valproic acid." | 3.71 | Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency. ( Glocker, FX; Jaksch, M; Ketelsen, UP; Kottlors, M; Lücking, CH; Weiner, S, 2001) |
| "Pancreatitis is a serious adverse effect of valproic acid (VPA)." | 3.70 | On the toxicity of valproic-acid. ( Alonso, R; Cuiña, L; Moreiras Plaza, M; Rodríguez Goyanes, G, 1999) |
| "An 11-year-old girl with juvenile neuronal ceroid lipofuscinosis developed acute pancreatitis secondary to valproic acid treatment, which resolved after discontinuation of the medication and conservative treatment." | 3.69 | Valproate-associated acute pancreatitis in a child with neuronal ceroid lipofuscinosis. ( Talwar, D, 1994) |
| "Lithium remains the mainstay of pharmacologic therapy for the majority of patients with bipolar disorder; however, significant numbers of patients with both classical bipolar disorder and syndromal variants fail to respond to lithium therapy." | 3.68 | Algorithm for patient management of acute manic states: lithium, valproate, or carbamazepine? ( Gerner, RH; Stanton, A, 1992) |
| "The development of acute pancreatitis in an 8-year-old boy being treated with valproic acid for simple absence spells is documented." | 3.66 | Pancreatitis associated with valproic acid therapy. ( Batalden, PB; Cloyd, J; Van Dyne, BJ, 1979) |
| "Seizures after intracerebral hemorrhage are a common complication and may adversely affect neurological outcome." | 2.79 | Protocol for seizure prophylaxis following intracerebral hemorrhage study (SPICH): a randomized, double-blind, placebo-controlled trial of short-term sodium valproate prophylaxis in patients with acute spontaneous supratentorial intracerebral hemorrhage. ( Cao, X; Fang, Y; Fu, M; Hu, X; Li, H; Li, X; Lin, S; Liu, M; Liu, W; You, C; Zhang, H, 2014) |
| "Risperidone was shown to have significant anti-manic effects which was observed as early as week 1, following start of treatment." | 2.77 | Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania. ( Hsu, MC; Kuo, CC; Ouyang, WC; Yeh, IN, 2012) |
| " The daily divalproex ER dosage was initiated at 20 mg/kg." | 2.75 | A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania. ( Bowden, CL; Collins, M; Hirschfeld, RM; Vigna, NV; Wozniak, P, 2010) |
| " Adverse events were systematically recorded throughout the study." | 2.74 | Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study. ( Chopra, D; Gupta, NK; Kakkar, AK; Kataria, D; Rehan, HS; Unni, KE, 2009) |
| "Thirty-six patients established on migraine prophylaxis were administered 500 mg sodium valproate intravenously against acute migraine attacks." | 2.73 | Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine. ( Marková, J; Mastík, J; Waberzinek, G, 2007) |
| " Daily dosage was initiated at 25 mg/kg, increased 500 mg on day 3, and adjusted to serum valproate concentrations of 85 to 125 microg/mL." | 2.72 | A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania. ( Abi-Saab, W; Bowden, CL; Calabrese, JR; Collins, MA; Rubenfaer, LM; Saltarelli, M; Swann, AC; Wozniak, PJ, 2006) |
| "Persistence of invalidating action myoclonus is a major problem." | 2.72 | Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease. ( Crespel, A; Gelisse, P; Genton, P, 2006) |
| " The aim of this study was to compare the effectiveness and tolerability of topiramate and divalproex in combination with risperidone for treating acute mania patients in a naturalistic treatment setting." | 2.71 | Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study. ( Bahk, WM; Choi, SK; Chung, SK; Jon, DI; Lee, JS; Pae, CU; Paik, IH; Shin, YC; Woo, JM; Yoon, BH, 2005) |
| "Both drugs were effective in acute migraine attacks with a trend in favor of iLAS." | 2.71 | Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks. ( Diener, HC; Leniger, T; Limmroth, V; Pageler, L; Stude, P, 2005) |
| "The termination time of seizure, doses of diazepam, mental symptoms and the continual time of mental symptoms were not significantly different among these three groups." | 2.71 | [Evaluation of therapeutic project on acute tetramethylene disulphotetramine poisoning and effect on intelligence in children]. ( Bai, H; Bai, YW; Ding, MB; Ji, JT; Lu, XR; Ma, PB; Sun, CY; Wang, HS; Zhang, HS; Zhang, SL; Zhou, XR, 2005) |
| " For patients with high-risk MDS, VPA may be combined with chemotherapy or demethylating drugs." | 2.71 | Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. ( Fox, F; Gattermann, N; Germing, U; Haas, R; Hildebrandt, B; Knipp, S; Kuendgen, A; Steidl, C; Strupp, C, 2005) |
| "The olanzapine treatment group had significantly greater mean improvement of mania ratings and a significantly greater proportion of patients achieving protocol-defined remission, compared with the divalproex treatment group." | 2.70 | Olanzapine versus divalproex in the treatment of acute mania. ( Altshuler, LL; Baker, RW; Breier, A; Gilmore, JA; Ketter, TA; Milton, DR; Risser, R; Suppes, T; Tohen, M; Tollefson, GA; Zarate, CA, 2002) |
| "Past substance abuse was evident in 34% of the bipolar sample and comprised most often alcoholism (82%), followed by cocaine (30%), marijuana (29%), sedative-hypnotic or amphetamine (21%), and opiate (13%) abuse." | 2.69 | A history of substance abuse complicates remission from acute mania in bipolar disorder. ( Garno, JL; Goldberg, JF; Kocsis, JH; Leon, AC; Portera, L, 1999) |
| " It also appears that rapid dosage increases for antimanic treatment can cause potentially severe side effects." | 2.69 | Tiagabine appears not to be efficacious in the treatment of acute mania. ( Amann, B; Erfurth, A; Grunze, H; Marcuse, A; Normann, C; Walden, J, 1999) |
| " No patient was removed from the study because of an adverse event." | 2.69 | Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients. ( Allen, MH; Hirschfeld, RM; Keck, PE; McEvoy, JP; Russell, JM, 1999) |
| "Sixty-five hospitalized patients who met the Research Diagnostic Criteria for bipolar disorder with mania were treated with divalproex, 750 mg/day for 2 days and then 1,000 mg/day on days 3-5; the dosage was subsequently adjusted as clinically indicated for the remainder of the 21-day study." | 2.68 | Relation of serum valproate concentration to response in mania. ( Bowden, CL; Calabrese, JR; Davis, JM; Goodnick, P; Janicak, PG; Kimmel, SE; Morris, DD; Orsulak, P; Risch, SC; Rush, AJ; Small, JG; Swann, AC, 1996) |
| " Serum valproate concentrations were measured three times weekly; an unblinded investigator then adjusted dosage to produce serum concentrations between 50 and 100 mg/L." | 2.67 | Valproate in the treatment of acute mania. A placebo-controlled study. ( Hudson, JI; Keck, PE; McElroy, SL; Pope, HG, 1991) |
| "Absence seizures have a significant impact on quality of life." | 2.49 | Absence seizures in children. ( Posner, E, 2013) |
| "Valproic acid (VPA) is an antiepileptic drug that is now used for a variety of neurological and psychiatric indications." | 2.45 | Extracorporeal elimination in acute valproic acid poisoning. ( Thanacoody, RH, 2009) |
| "Haloperidol was superior to quetiapine in efficacy at day 21 but similar at day 84." | 2.44 | Quetiapine for acute mania in bipolar disorder. ( Brahm, NC; Carnahan, RM; Gutierres, SL, 2007) |
| "Valproic acid (VPA) has been used as an anticonvulsant for decades." | 2.44 | Valproic acid for the treatment of myeloid malignancies. ( Gattermann, N; Kuendgen, A, 2007) |
| "There is a general agreement now that migraine is not only a vascular phenomenon but also a genetically determined heterogenic ion-channelopathy resulting in cortical-spreading-depression-like events, the temporary impairment of antinociceptive structures of the brainstem and the activation of the trigeminal-vascular system." | 2.44 | GABAergic drugs for the treatment of migraine. ( Limmroth, V; Puppe, A, 2007) |
| "Lamotrigine has also demonstrated significant efficacy in recent studies and has been approved by the FDA." | 2.42 | Bipolar depression: an overview. ( Oral, ET; Vahip, S, 2004) |
| "Lamotrigine has emerged as a first line treatment for bipolar depression, which is an area of weakness for other mood stabilizers." | 2.42 | Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders. ( Goodwin, FK; Lieberman, DZ, 2004) |
| "Fosphenytoin has recently been approved as a substitute for parenteral phenytoin." | 2.40 | New drug therapy for acute seizure management. ( Morton, LD; Pellock, JM; Rizkallah, E, 1997) |
| " This review summarizes efficacy results of key studies in manic-depressive illness, the increasingly practical findings regarding predictors of response, and the implications of the increasingly better understood adverse effect profile of lithium." | 2.40 | Key treatment studies of lithium in manic-depressive illness: efficacy and side effects. ( Bowden, CL, 1998) |
| "5 and year-old epileptic boy with severe acute pancreatitis which appeared 39 months after starting treatment with sodium valproate (VAP) at a daily dosage of 26." | 2.38 | [Acute pancreatitis caused by sodium valproate. Review of the literature apropos of a case in a child]. ( Boussard, N; de Miscault, G; Rose, E; Thome, M, 1991) |
| "A case of valproate induced acute pancreatitis operated as surgical abdomen has been reported here." | 1.72 | Valproate Induced Acute Pancreatitis - A Unique Case Report. ( Chauhan, V; Garg, GK; Kapur, A; Sharma, M, 2022) |
| "The risk of seizure relapse was estimated as 43." | 1.56 | Antiepileptic drugs for acute encephalitic patients presented with seizure. ( Chen, L; He, S; Lai, W; Li, W; Peng, A; Qiu, X; Zhang, L, 2020) |
| "Valproic acid (VPA) has shown potent anti-inflammatory effect and attenuates acute lung injury." | 1.48 | Valproic acid attenuates the risk of acute respiratory failure in patients with subarachnoid hemorrhage. ( Chien, WC; Chu, SJ; Chung, CH; Chung, TT; Liao, WI; Tsai, SH; Wang, JC, 2018) |
| "Background The development of novel migraine therapies has been slow, in part because of the small number of clinically relevant animal models." | 1.43 | The effects of acute and preventive migraine therapies in a mouse model of chronic migraine. ( Charles, A; McGuire, B; Pradhan, AA; Tarash, I; Tipton, AF, 2016) |
| "Hemorrhage is a major cause of morbidity and mortality among trauma patients." | 1.43 | Valproic acid-mediated myocardial protection of acute hemorrhagic rat via the BCL-2 pathway. ( He, M; He, Y; Kuai, Q; Li, W; Qiao, Z; Ren, S; Wang, C; Wang, X; Wang, Y; Yu, Q, 2016) |
| "Headaches are common in the pediatric population, and increase in prevalence with age." | 1.42 | Intravenous Sodium Valproate for Acute Pediatric Headache. ( Hansen, M; O'Brien, P; Sheridan, D; Sun, B, 2015) |
| "Cases of acute pancreatitis caused by sodium valproate (VPA) have been reported by many authors thus far." | 1.40 | Development of acute pancreatitis caused by sodium valproate in a patient with bipolar disorder on hemodialysis for chronic renal failure: a case report. ( Okayasu, H; Osone, A; Ozeki, Y; Shimoda, K; Shinozaki, T, 2014) |
| "This audit was conducted on acute psychiatric in-patient wards with the aim of establishing if valproate prescribing in acute mania followed evidence-based guidelines with particular emphasis on formulations used and whether accelerated valproate dosing was employed." | 1.38 | Valproate in acute mania: is our practice evidence based? ( Macritchie, K; Mead, A; Vasudev, K; Young, AH, 2012) |
| "Chorea is a rare and dose dependent side effect of valproate." | 1.37 | Acute chorea caused by valproate in an elderly. ( Cras, P; Helsen, G; van de Velde, K, 2011) |
| "Azathioprine was the most frequent causative factor (three cases in two patients); all the other causative drugs were documented only in single cases: mesalazine, dexamethasone, ramipril, mycophenolate mofetil, cytarabine, and valproate." | 1.36 | Incidence, severity, and etiology of drug-induced acute pancreatitis. ( Procházka, M; Procházka, V; Urbánek, K; Vinklerová, I, 2010) |
| " We conclude that valproic acid+ATRA+theophylline combined with 6-mercaptopurin or hydroxyurea can be safe and effective in palliative treatment of human AML." | 1.36 | Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases. ( Bruserud, Ø; Fredly, H; Gjertsen, BT; Stapnes Bjørnsen, C, 2010) |
| " Frequent monitoring of serum levels to support dosing decisions is important to inform better clinical decision making, especially when a loading strategy is used." | 1.35 | Mood stabilizer loading versus titration in acute mania: audit of clinical practice. ( Fraser, A; Robinson, G; Wheeler, A, 2008) |
| "Valproic acid is an effective anti-epileptic medication often used for long-term control of seizure disorders that has been implicated in hematological toxicities, including rare reports of myelodysplasia and acute leukemia." | 1.35 | Translocation-positive acute myeloid leukemia associated with valproic acid therapy. ( Ben-Ezra, J; Massey, GV; Riley, RS; Russell, EC; Williams, DC, 2008) |
| "Acute pancreatitis is rarely seen in children, and it is often drug induced." | 1.35 | Acute hemorrhagic pancreatitis due to the use of valproic acid in a child. ( Köse, G; Ozaydin, E; Yükselgüngör, H, 2008) |
| "5 microg/mL) (Li/DVP) (for 3-6 weeks) in four double-blind, placebo-controlled studies according to a predetermined dosing schedule." | 1.34 | Quetiapine in the treatment of acute mania: target dose for efficacious treatment. ( Goldberg, JF; Mullen, J; Paulsson, B; Vågerö, M; Vieta, E, 2007) |
| " Adverse event reporting, Simpson Angus Scale (SAS), and Barnes Akathisia Rating Scale (BARS) scores were recorded." | 1.34 | Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder. ( Adler, CM; Brecher, M; Fleck, DE; Strakowski, SM, 2007) |
| "The aim of this analysis was to compare the rates of remission/euthymia in patients with bipolar mania receiving quetiapine in combination with lithium/divalproex (QTP+Li/DVP) versus placebo (PBO) in combination with Li/DVP (PBO+Li/DVP)." | 1.34 | Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania. ( Mullen, J; Paulsson, B; Sussman, N; Vågerö, M, 2007) |
| "Ertapenem was discontinued, and his divalproex sodium dosage was increased further." | 1.34 | Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy. ( Lunde, JL; Nelson, RE; Storandt, HF, 2007) |
| "On treatment with olanzapine, valproic acid, and perazine there was only moderate improvement." | 1.33 | Acute psychosis with a mediastinal carcinoma metastasis. ( Connemann, BJ; Freudenmann, RW; Kassubek, J; Schönfeldt-Lecuona, C; Tumani, H, 2005) |
| "Valproic acid has been previously associated with hematologic toxicity, including a reversible myelodysplasia-like syndrome without chromosomal abnormalities." | 1.33 | Acute leukemia associated with valproic acid treatment: a novel mechanism for leukemogenesis? ( Bair, AK; Coyle, TE; Mehdi, S; Stein, C; Vajpayee, N; Wright, J, 2005) |
| "For the management of bipolar depression, new data support quetiapine monotherapy as a first-line option." | 1.33 | Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007. ( Beaulieu, S; Kennedy, SH; MacQueen, G; McIntyre, RS; O'Donovan, C; Parikh, SV; Sharma, V; Yatham, LN, 2006) |
| "Intravenous VPA loading is safe and effective for treating acute seizure emergencies in children." | 1.32 | Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures. ( Cunanan, C; Mills, S; Thompson, N; Yu, KT, 2003) |
| "We report a patient with focal epilepsy and latent hereditary coproporphyria who had exacerbation of clinical symptoms of porphyria under treatment with valproate and primidone and was then treated with levetiracetam without exacerbation of clinically latent porphyria." | 1.32 | Levetiracetam in focal epilepsy and hepatic porphyria: a case report. ( Meencke, HJ; Paul, F, 2004) |
| "An acute pancreatitis is relatively common after intravenous administration." | 1.32 | [An acute pancreatitis in a child caused by Na-valproate]. ( Jeremić, Lj; Jovanović, M; Karadzić, D; Madić, J; Stanojević, G; Stojanović, M; Zivanović, D, 2004) |
| "Acute pancreatitis has been associated with a number of medications, including valproate (VPA)." | 1.31 | Acute pancreatitis coincident with valproate use: a critical review. ( Deaton, R; Pellock, JM; Sommerville, KW; Wilder, BJ, 2002) |
| "an elderly patient presented with acute confusion and was found to have nonconvulsive status epilepticus." | 1.31 | Nonconvulsive status epilepticus causing acute confusion. ( Mitchell, SC; Pollock, LM, 2000) |
| "Patients with migraines have typically been given one group of medications for abortive treatment and another for preventative." | 1.31 | Use of intravenous valproate sodium in status migraine. ( Norton, J, 2000) |
| "The onset of coma may have been related to inhibition of beta-oxidation in the mitochondria, which was reversible by elimination of plasma VPA by DHP." | 1.30 | Successful treatment by direct hemoperfusion of coma possibly resulting from mitochondrial dysfunction in acute valproate intoxication. ( Kuhara, T; Maeyama, R; Matsumoto, I; Matsumoto, J; Ogawa, H; Okudaira, K; Shinka, T, 1997) |
| "To conduct a pilot study on the safety and tolerability of a dosage strategy for divalproex sodium beginning with 30 mg/kg/day." | 1.30 | Tolerability of oral loading of divalproex sodium in the treatment of acute mania. ( Hirschfeld, RM; Martinez, JM; Russell, JM, 1998) |
| "The methemoglobinemia was readily reversed with the administration of methylene blue." | 1.30 | Acute valproate ingestion induces symptomatic methemoglobinemia. ( Lynch, A; Tobias, JD, 1998) |
| " Seizures became diurnal and frequent, not modified by carbamazepine (CBZ) or valproate (VPA) but responding to VPA and lamotrigine (LTG) with recommended dosage schedules for this combination." | 1.30 | Paradoxic reaction to lamotrigine in a child with benign focal epilepsy of childhood with centrotemporal spikes. ( Boyd, S; Catania, S; Cross, H; de Sousa, C, 1999) |
| "We report a fatal case of haemorrhagic pancreatic necrosis in a 15-year-old mentally retarded epileptic male who had been taking sodium valproate (VPA) in the recommended dosage for one and a half years." | 1.29 | [Fatal pancreatitis associated with valproate therapy]. ( Engelmann, MD; Henriksen, SD; Tingsgaard, LK, 1995) |
| " To provide further data on the safety and efficacy of valproate oral loading in the treatment of acute mania, we evaluated 13 consecutive patients with acute manic syndromes who received valproate initiated at a dosage of 20 mg/kg/day." | 1.29 | Valproate as a loading treatment in acute mania. ( Bennett, JA; Keck, PE; McElroy, SL; Tugrul, KC, 1993) |
| "We treated 15 children with Sydenham's chorea with sodium valproate at a dose of 15 to 20 mg/kg/d." | 1.28 | Effectiveness of sodium valproate in the treatment of Sydenham's chorea. ( al-Saleh, Q; Daoud, AS; Shakir, R; Zaki, M, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 28 (11.24) | 18.7374 |
| 1990's | 54 (21.69) | 18.2507 |
| 2000's | 118 (47.39) | 29.6817 |
| 2010's | 44 (17.67) | 24.3611 |
| 2020's | 5 (2.01) | 2.80 |
| Authors | Studies |
|---|---|
| Chauhan, V | 1 |
| Sharma, M | 1 |
| Kapur, A | 1 |
| Garg, GK | 1 |
| Yanaga, M | 1 |
| Okamoto, N | 1 |
| Hashimoto, R | 1 |
| Igata, R | 1 |
| Konishi, Y | 1 |
| Ikenouchi, A | 1 |
| Isomoto, N | 1 |
| Shinkai, T | 1 |
| Harada, M | 1 |
| Yoshimura, R | 1 |
| Sanoria, A | 1 |
| Arora, R | 1 |
| Dokania, P | 1 |
| Peng, X | 1 |
| Yan, Y | 1 |
| Chen, R | 1 |
| Wang, X | 3 |
| Xu, X | 1 |
| Peng, A | 1 |
| Lai, W | 1 |
| Li, W | 2 |
| Qiu, X | 1 |
| Zhang, L | 1 |
| He, S | 1 |
| Chen, L | 1 |
| Finsterer, J | 1 |
| Lyons, C | 1 |
| Godoy, F | 1 |
| Vanden Driessche, K | 1 |
| Liao, WI | 1 |
| Chien, WC | 1 |
| Chung, CH | 1 |
| Wang, JC | 1 |
| Chung, TT | 1 |
| Chu, SJ | 1 |
| Tsai, SH | 1 |
| Omar, M | 1 |
| Abdul, R | 1 |
| Panday, A | 1 |
| Teelucksingh, S | 1 |
| Quan, W | 1 |
| Shao, Q | 1 |
| Zhang, H | 2 |
| Liu, FH | 1 |
| Zhang, XH | 1 |
| Gupta, J | 1 |
| Sinha, R | 1 |
| Jauhari, P | 1 |
| Malik, R | 1 |
| Chakrabarty, B | 1 |
| Gulati, S | 1 |
| McKnight, RF | 1 |
| de La Motte de Broöns de Vauvert, SJGN | 1 |
| Chesney, E | 1 |
| Amit, BH | 1 |
| Geddes, J | 2 |
| Cipriani, A | 1 |
| Yaman, A | 1 |
| Kendirli, T | 1 |
| Odek, C | 1 |
| Bektaş, O | 1 |
| Kuloğlu, Z | 1 |
| Koloğlu, M | 1 |
| Ince, E | 1 |
| Deda, G | 1 |
| Shekh-Ahmad, T | 1 |
| Hen, N | 1 |
| McDonough, JH | 1 |
| Yagen, B | 1 |
| Bialer, M | 1 |
| Hu, X | 1 |
| Fang, Y | 1 |
| Li, H | 1 |
| Liu, W | 1 |
| Lin, S | 2 |
| Fu, M | 1 |
| Li, X | 1 |
| Cao, X | 1 |
| You, C | 1 |
| Liu, M | 1 |
| Hranov, LG | 1 |
| Marinova, P | 1 |
| Stoyanova, M | 1 |
| Pandova, M | 1 |
| Hranov, G | 1 |
| Posner, E | 2 |
| Okayasu, H | 1 |
| Shinozaki, T | 1 |
| Osone, A | 1 |
| Ozeki, Y | 1 |
| Shimoda, K | 1 |
| Veri, K | 1 |
| Uibo, O | 1 |
| Talvik, I | 1 |
| Talvik, T | 1 |
| Mazaheri, S | 1 |
| Poorolajal, J | 1 |
| Hosseinzadeh, A | 1 |
| Fazlian, MM | 1 |
| Sheridan, D | 1 |
| Sun, B | 1 |
| O'Brien, P | 1 |
| Hansen, M | 1 |
| Glue, P | 1 |
| Herbison, P | 1 |
| Kleimann, A | 1 |
| Schrader, V | 1 |
| Stübner, S | 1 |
| Greil, W | 2 |
| Kahl, KG | 1 |
| Bleich, S | 1 |
| Grohmann, R | 1 |
| Frieling, H | 1 |
| Toto, S | 1 |
| Tipton, AF | 1 |
| Tarash, I | 1 |
| McGuire, B | 1 |
| Charles, A | 1 |
| Pradhan, AA | 1 |
| Wang, C | 1 |
| Wang, Y | 2 |
| Qiao, Z | 1 |
| Kuai, Q | 1 |
| He, M | 1 |
| He, Y | 1 |
| Ren, S | 1 |
| Yu, Q | 1 |
| Hirose, T | 1 |
| Jackson, R | 1 |
| Toubia, N | 1 |
| Dhaliwal, G | 1 |
| Bottomley, SS | 1 |
| Bronze, MS | 1 |
| Gilad, R | 1 |
| Izkovitz, N | 1 |
| Dabby, R | 1 |
| Rapoport, A | 1 |
| Sadeh, M | 1 |
| Weller, B | 1 |
| Lampl, Y | 1 |
| Wheeler, A | 1 |
| Robinson, G | 1 |
| Fraser, A | 1 |
| Ketter, TA | 6 |
| Kakkar, AK | 1 |
| Rehan, HS | 1 |
| Unni, KE | 1 |
| Gupta, NK | 1 |
| Chopra, D | 1 |
| Kataria, D | 1 |
| Hauswald, S | 1 |
| Duque-Afonso, J | 1 |
| Wagner, MM | 1 |
| Schertl, FM | 1 |
| Lübbert, M | 1 |
| Peschel, C | 1 |
| Keller, U | 1 |
| Licht, T | 1 |
| Radaelli, E | 1 |
| Marchesi, F | 1 |
| Patton, V | 1 |
| Scanziani, E | 1 |
| Guevara-Campos, J | 1 |
| González-Guevara, L | 1 |
| Vacaro-Bolívar, I | 1 |
| Rojas, JM | 1 |
| Thanacoody, RH | 1 |
| Vannaprasaht, S | 1 |
| Tiamkao, S | 1 |
| Sirivongs, D | 1 |
| Piyavhatkul, N | 1 |
| Wang, PW | 1 |
| Nowakowska, C | 1 |
| Chandler, RA | 1 |
| Hill, SJ | 1 |
| Nam, JY | 1 |
| Culver, JL | 1 |
| Keller, KL | 1 |
| Smith, LA | 1 |
| Cornelius, VR | 1 |
| Azorin, JM | 1 |
| Perugi, G | 1 |
| Vieta, E | 2 |
| Young, AH | 3 |
| Bowden, CL | 11 |
| Bond, DJ | 1 |
| Lam, RW | 2 |
| Yatham, LN | 3 |
| Gonçalves, JA | 1 |
| Santos, C | 1 |
| Montalbán, JM | 1 |
| Filipe, RA | 1 |
| Chorão, R | 1 |
| Freixo, J | 1 |
| Ramalheiro, A | 1 |
| Bernardo, A | 1 |
| Iglesias, AB | 1 |
| Rocha, E | 1 |
| Chou, JC | 1 |
| Hirschfeld, RM | 5 |
| Vigna, NV | 1 |
| Wozniak, P | 2 |
| Collins, M | 1 |
| Vinklerová, I | 1 |
| Procházka, M | 1 |
| Procházka, V | 1 |
| Urbánek, K | 1 |
| Goodyear, O | 1 |
| Agathanggelou, A | 1 |
| Novitzky-Basso, I | 1 |
| Siddique, S | 1 |
| McSkeane, T | 1 |
| Ryan, G | 1 |
| Vyas, P | 1 |
| Cavenagh, J | 1 |
| Stankovic, T | 1 |
| Moss, P | 1 |
| Craddock, C | 2 |
| Campos, RN | 1 |
| Costa, LF | 1 |
| Bio, DS | 1 |
| Soeiro de Souza, MG | 1 |
| Garcia, CR | 1 |
| Demétrio, FN | 1 |
| Moreno, DH | 1 |
| Moreno, RA | 1 |
| Kumar, A | 1 |
| Gupta, M | 1 |
| Jiloha, RC | 1 |
| Tekur, U | 1 |
| Belaizi, M | 1 |
| Mehssani, J | 1 |
| Yahyaoui, M | 1 |
| Fajri, A | 1 |
| Fredly, H | 1 |
| Stapnes Bjørnsen, C | 1 |
| Gjertsen, BT | 1 |
| Bruserud, Ø | 1 |
| Dichtwald, S | 1 |
| Dahan, E | 1 |
| Adi, N | 1 |
| Moses, A | 1 |
| Sorkine, P | 1 |
| Sachs, GS | 5 |
| Ice, KS | 1 |
| Chappell, PB | 1 |
| Schwartz, JH | 1 |
| Gurtovaya, O | 1 |
| Vanderburg, DG | 1 |
| Kasuba, B | 1 |
| Bai, HX | 1 |
| Ma, MH | 1 |
| Orabi, AI | 1 |
| Park, A | 1 |
| Latif, SU | 1 |
| Bhandari, V | 1 |
| Husain, SZ | 1 |
| van de Velde, K | 1 |
| Cras, P | 1 |
| Helsen, G | 1 |
| Vasudev, A | 1 |
| Macritchie, K | 2 |
| Vasudev, K | 2 |
| Watson, S | 1 |
| Szegedi, A | 1 |
| Calabrese, JR | 9 |
| Stet, L | 1 |
| Mackle, M | 1 |
| Zhao, J | 1 |
| Panagides, J | 1 |
| Papaseit, E | 1 |
| Farré, M | 1 |
| López, MJ | 1 |
| Clemente, C | 1 |
| Campodarve, I | 1 |
| Pons, S | 1 |
| Gonzva, J | 1 |
| Prunet, B | 1 |
| Gaillard, T | 1 |
| Brisou, P | 1 |
| Vest, P | 1 |
| Emile, L | 1 |
| Ouyang, WC | 1 |
| Hsu, MC | 1 |
| Yeh, IN | 1 |
| Kuo, CC | 1 |
| Mead, A | 1 |
| Nie, D | 1 |
| Huang, K | 1 |
| Yin, S | 1 |
| Li, Y | 1 |
| Xie, S | 1 |
| Ma, L | 1 |
| Wu, Y | 1 |
| Xiao, J | 1 |
| Jakobović, J | 1 |
| Butković, D | 1 |
| Popović, L | 1 |
| Skarić, I | 1 |
| Mikecin, L | 1 |
| Bakhshayesh, B | 1 |
| Seyed Saadat, SM | 1 |
| Rezania, K | 1 |
| Hatamian, H | 1 |
| Hossieninezhad, M | 1 |
| Delbello, MP | 2 |
| Schwiers, ML | 1 |
| Rosenberg, HL | 1 |
| Strakowski, SM | 4 |
| Pellock, JM | 3 |
| Wilder, BJ | 1 |
| Deaton, R | 1 |
| Sommerville, KW | 3 |
| Oluboka, OJ | 1 |
| Bird, DC | 1 |
| Kutcher, S | 1 |
| Kusumakar, V | 1 |
| Reischies, FM | 2 |
| Hartikainen, J | 2 |
| Berghöfer, AM | 1 |
| Berghöfer, A | 1 |
| Shahar, E | 2 |
| Barak, S | 1 |
| Alderfer, BS | 1 |
| Allen, MH | 3 |
| Reif, A | 1 |
| Hamelbeck, B | 1 |
| Pfuhlmann, B | 1 |
| Frye, MA | 1 |
| Gitlin, MJ | 1 |
| Altshuler, LL | 3 |
| Maguire, GA | 1 |
| Phillips, G | 1 |
| Grauso-Eby, NL | 1 |
| Goldfarb, O | 1 |
| Feldman-Winter, LB | 1 |
| McAbee, GN | 1 |
| Revicki, DA | 1 |
| Paramore, LC | 1 |
| Swann, AC | 5 |
| Zajecka, JM | 1 |
| Wheless, JW | 2 |
| Yu, KT | 1 |
| Mills, S | 1 |
| Thompson, N | 1 |
| Cunanan, C | 1 |
| Tanen, DA | 1 |
| Miller, S | 1 |
| French, T | 1 |
| Riffenburgh, RH | 1 |
| Tohen, M | 6 |
| Zarate, CA | 4 |
| Suppes, T | 4 |
| Frye, M | 1 |
| Altshuler, L | 1 |
| Zajecka, J | 1 |
| Schuh, LM | 1 |
| Risser, RC | 2 |
| Brown, E | 1 |
| Baker, RW | 4 |
| Birnbaum, AK | 1 |
| Kriel, RL | 1 |
| Norberg, SK | 1 |
| Wical, BS | 1 |
| Le, DN | 1 |
| Leppik, IE | 1 |
| Cloyd, JC | 1 |
| Baker, JD | 2 |
| Tracy, K | 1 |
| Grunze, H | 4 |
| Dittmann, S | 1 |
| Imbenotte, M | 1 |
| Azaroual, N | 1 |
| Cartigny, B | 1 |
| Vermeersch, G | 1 |
| Lhermitte, M | 1 |
| Phrolov, K | 1 |
| Applebaum, J | 1 |
| Levine, J | 2 |
| Miodovnick, H | 1 |
| Belmaker, RH | 1 |
| Paul, F | 1 |
| Meencke, HJ | 1 |
| Tang, R | 1 |
| Faussat, AM | 1 |
| Majdak, P | 1 |
| Perrot, JY | 1 |
| Chaoui, D | 1 |
| Legrand, O | 1 |
| Marie, JP | 1 |
| Yoshikawa, H | 1 |
| Duggal, HS | 1 |
| Oral, ET | 1 |
| Vahip, S | 1 |
| Vazquez, BR | 1 |
| Kanner, AM | 1 |
| Ramsay, RE | 1 |
| Morton, L | 1 |
| Lieberman, DZ | 1 |
| Goodwin, FK | 1 |
| Bahk, WM | 1 |
| Shin, YC | 1 |
| Woo, JM | 1 |
| Yoon, BH | 1 |
| Lee, JS | 1 |
| Jon, DI | 1 |
| Chung, SK | 1 |
| Choi, SK | 1 |
| Paik, IH | 1 |
| Pae, CU | 1 |
| Schönfeldt-Lecuona, C | 1 |
| Freudenmann, RW | 1 |
| Tumani, H | 1 |
| Kassubek, J | 1 |
| Connemann, BJ | 1 |
| Laghate, VD | 1 |
| Gupta, SB | 1 |
| Leniger, T | 1 |
| Pageler, L | 1 |
| Stude, P | 1 |
| Diener, HC | 1 |
| Limmroth, V | 2 |
| Coves-Orts, FJ | 1 |
| Borrás-Blasco, J | 1 |
| Navarro-Ruiz, A | 1 |
| Murcia-López, A | 1 |
| Palacios-Ortega, F | 1 |
| Coyle, TE | 1 |
| Bair, AK | 1 |
| Stein, C | 1 |
| Vajpayee, N | 1 |
| Mehdi, S | 1 |
| Wright, J | 1 |
| Muzina, DJ | 2 |
| Elhaj, O | 1 |
| Gajwani, P | 2 |
| Gao, K | 2 |
| Bai, H | 1 |
| Zhang, SL | 1 |
| Zhang, HS | 1 |
| Ji, JT | 1 |
| Ma, PB | 1 |
| Wang, HS | 1 |
| Bai, YW | 1 |
| Zhou, XR | 1 |
| Ding, MB | 1 |
| Lu, XR | 1 |
| Sun, CY | 1 |
| Houben, ML | 1 |
| Wilting, I | 1 |
| Stroink, H | 1 |
| van Dijken, PJ | 1 |
| Patrizi, A | 1 |
| Savoia, F | 1 |
| Negosanti, F | 1 |
| Posar, A | 1 |
| Santucci, M | 1 |
| Neri, I | 1 |
| Pilatrino, C | 1 |
| Cilloni, D | 1 |
| Messa, E | 1 |
| Morotti, A | 1 |
| Giugliano, E | 1 |
| Pautasso, M | 1 |
| Familiari, U | 1 |
| Cappia, S | 1 |
| Pelicci, PG | 1 |
| Lo Coco, F | 1 |
| Saglio, G | 1 |
| Guerrasio, A | 1 |
| Zhu, B | 1 |
| Tunis, SL | 1 |
| Zhao, Z | 1 |
| Lage, MJ | 1 |
| Shi, L | 1 |
| Stojanović, M | 2 |
| Zivanović, D | 1 |
| Madić, J | 1 |
| Karadzić, D | 1 |
| Stanojević, G | 1 |
| Jovanović, M | 1 |
| Jeremić, Lj | 1 |
| Bradbury, CA | 1 |
| Khanim, FL | 1 |
| Hayden, R | 1 |
| Bunce, CM | 1 |
| White, DA | 1 |
| Drayson, MT | 1 |
| Turner, BM | 1 |
| Liddle, PF | 1 |
| Adam, MJ | 1 |
| Solomons, K | 1 |
| Chinnapalli, M | 1 |
| Ruth, TJ | 1 |
| Kuendgen, A | 3 |
| Knipp, S | 2 |
| Fox, F | 1 |
| Strupp, C | 1 |
| Hildebrandt, B | 2 |
| Steidl, C | 2 |
| Germing, U | 2 |
| Haas, R | 2 |
| Gattermann, N | 3 |
| Schmid, M | 1 |
| Schlenk, R | 1 |
| Dohner, H | 1 |
| Chiu, CC | 1 |
| Huang, SY | 1 |
| Chen, CC | 1 |
| Su, KP | 1 |
| Ritter, M | 1 |
| Kattmann, D | 1 |
| Teichler, S | 1 |
| Hartmann, O | 1 |
| Samuelsson, MK | 1 |
| Burchert, A | 1 |
| Bach, JP | 1 |
| Kim, TD | 1 |
| Berwanger, B | 1 |
| Thiede, C | 1 |
| Jäger, R | 1 |
| Ehninger, G | 1 |
| Schäfer, H | 1 |
| Ueki, N | 1 |
| Hayman, MJ | 1 |
| Eilers, M | 1 |
| Neubauer, A | 1 |
| Wozniak, PJ | 3 |
| Blum, W | 1 |
| Marcucci, G | 1 |
| Embacher, N | 1 |
| Karner, E | 1 |
| Wanschitz, J | 1 |
| Beer, R | 1 |
| Trinka, E | 1 |
| Kemp, DE | 2 |
| Xia, G | 1 |
| Rubenfaer, LM | 1 |
| Collins, MA | 2 |
| Abi-Saab, W | 1 |
| Saltarelli, M | 1 |
| Kennedy, SH | 1 |
| O'Donovan, C | 1 |
| Parikh, SV | 1 |
| MacQueen, G | 1 |
| McIntyre, RS | 2 |
| Sharma, V | 1 |
| Beaulieu, S | 1 |
| Contini, P | 1 |
| Zocchi, MR | 1 |
| Pierri, I | 1 |
| Albarello, A | 1 |
| Poggi, A | 1 |
| Genton, P | 1 |
| Gelisse, P | 1 |
| Crespel, A | 1 |
| Williams, DC | 1 |
| Massey, GV | 1 |
| Russell, EC | 1 |
| Riley, RS | 1 |
| Ben-Ezra, J | 1 |
| Waberzinek, G | 1 |
| Marková, J | 1 |
| Mastík, J | 1 |
| Goldberg, JF | 4 |
| Mullen, J | 2 |
| Vågerö, M | 2 |
| Paulsson, B | 3 |
| Adler, CM | 1 |
| Fleck, DE | 1 |
| Brecher, M | 1 |
| Sussman, N | 1 |
| Konarski, JZ | 1 |
| Jones, M | 1 |
| Adli, M | 1 |
| Bauer, M | 1 |
| Berger, M | 1 |
| Bergmann, A | 1 |
| Bräunig, P | 1 |
| Bschor, T | 1 |
| Falkai, P | 1 |
| Gastpar, M | 1 |
| Kasper, S | 1 |
| Krüger, S | 1 |
| Laux, G | 1 |
| Müller, WE | 1 |
| Naber, D | 1 |
| Walden, J | 4 |
| Cheng, YC | 1 |
| Lin, H | 1 |
| Huang, MJ | 1 |
| Chow, JM | 1 |
| Liu, HE | 1 |
| Patel, NC | 1 |
| Patrick, DM | 1 |
| Youngstrom, EA | 1 |
| Brahm, NC | 1 |
| Gutierres, SL | 1 |
| Carnahan, RM | 1 |
| Lunde, JL | 1 |
| Nelson, RE | 1 |
| Storandt, HF | 1 |
| Schenkel, LS | 1 |
| Pavuluri, MN | 1 |
| Herbener, ES | 1 |
| Harral, EM | 1 |
| Sweeney, JA | 1 |
| Feifel, D | 1 |
| Gardner-Schuster, EE | 1 |
| Puppe, A | 1 |
| Ozaydin, E | 1 |
| Yükselgüngör, H | 1 |
| Köse, G | 1 |
| McElroy, SL | 7 |
| Keck, PE | 9 |
| Aliyev, NA | 1 |
| Aliyev, ZN | 1 |
| Lian, XY | 1 |
| Khan, FA | 1 |
| Stringer, JL | 1 |
| Kummer, A | 1 |
| Maia, DP | 1 |
| Cardoso, F | 1 |
| Teixeira, AL | 1 |
| Ghaemi, SN | 3 |
| Gilmer, WS | 1 |
| Zablotsky, B | 1 |
| Kelley, ME | 1 |
| Bauer, AD | 1 |
| Fleck, J | 1 |
| Filkowski, MM | 1 |
| Stan, VA | 1 |
| Dunn, RT | 1 |
| Cesková, E | 1 |
| Svestka, J | 1 |
| Obrovská, V | 1 |
| Rysánek, R | 1 |
| Náhunek, K | 1 |
| Mahlknecht, U | 1 |
| Schönbein, C | 1 |
| Frazee, LA | 1 |
| Foraker, KC | 1 |
| El-Mallakh, RS | 1 |
| Weisler, RH | 1 |
| Hirschfeld, R | 1 |
| Cutler, AJ | 1 |
| Gazda, T | 1 |
| Keck, P | 1 |
| Kalali, AH | 1 |
| Garcia-Merino, JA | 1 |
| Lopez-Lozano, JJ | 1 |
| Ware, S | 1 |
| Millward-Sadler, GH | 1 |
| Eeg-Olofsson, O | 1 |
| Lindskog, U | 1 |
| Schnabel, R | 1 |
| Rambeck, B | 1 |
| Janssen, F | 1 |
| Torelli, D | 1 |
| Galeone, D | 1 |
| Lamontanara, G | 1 |
| Williams, LH | 1 |
| Reynolds, RP | 1 |
| Emery, JL | 1 |
| Bourguignon, A | 1 |
| Monfort, JC | 1 |
| de Medeiros, P | 1 |
| Cadet, B | 1 |
| Chaneac, D | 1 |
| Addison, GM | 1 |
| Gordon, NS | 1 |
| Lankisch, PG | 1 |
| Criée, CP | 1 |
| Faller, JP | 1 |
| Girardel, M | 1 |
| Sauder, P | 1 |
| Haegy, JM | 1 |
| Simon, G | 1 |
| Garnier, R | 1 |
| Fournier, E | 1 |
| Le Bihan, G | 1 |
| Coquerel, A | 1 |
| Houssin, D | 1 |
| Bourreille, J | 1 |
| Szekely, AM | 1 |
| Bismuth, H | 1 |
| Hémet, J | 1 |
| Samson, M | 1 |
| Ng, JY | 1 |
| Disney, AP | 1 |
| Jones, TE | 1 |
| Purdie, G | 1 |
| Callaghan, N | 1 |
| O'Hare, J | 1 |
| O'Driscoll, D | 1 |
| O'Neill, B | 1 |
| Daly, M | 1 |
| Engelmann, MD | 1 |
| Henriksen, SD | 1 |
| Tingsgaard, LK | 1 |
| Werth, B | 1 |
| Kuhn, M | 1 |
| Hartmann, K | 1 |
| Reinhart, WH | 1 |
| Evans, RJ | 1 |
| Miranda, RN | 1 |
| Jordan, J | 1 |
| Krolikowski, FJ | 1 |
| Papatheodorou, G | 2 |
| Kutcher, SP | 2 |
| Katic, M | 1 |
| Szalai, JP | 1 |
| Croizet, O | 1 |
| Louvel, D | 1 |
| Teulière, JP | 1 |
| Buscail, L | 1 |
| Escourrou, J | 1 |
| Frexinos, J | 1 |
| Brady, KT | 1 |
| Sonne, SC | 1 |
| Anton, R | 1 |
| Ballenger, JC | 1 |
| Anderson, GD | 1 |
| Gidal, BE | 1 |
| Hendryx, RJ | 1 |
| Awan, AB | 1 |
| Temkin, NR | 1 |
| Wilensky, AJ | 1 |
| Winn, HR | 1 |
| Hering, R | 1 |
| Steiner, TJ | 1 |
| Katsumori, H | 1 |
| Nagaki, S | 1 |
| Matsuzaki, M | 1 |
| Funatsuka, M | 1 |
| Fukuyama, Y | 2 |
| Talwar, D | 1 |
| Tugrul, KC | 3 |
| Bennett, JA | 5 |
| Momota, T | 1 |
| Ito, S | 1 |
| Kobayashi, K | 1 |
| Mimasu, S | 1 |
| Kuniya, T | 1 |
| Stanton, SP | 2 |
| Nabulsi, AA | 1 |
| Taylor, JL | 1 |
| Henke, CJ | 1 |
| Chmiel, JJ | 1 |
| Janicak, PG | 1 |
| Orsulak, P | 1 |
| Davis, JM | 1 |
| Goodnick, P | 1 |
| Small, JG | 1 |
| Rush, AJ | 2 |
| Kimmel, SE | 2 |
| Risch, SC | 1 |
| Morris, DD | 2 |
| Centorrino, F | 1 |
| Hegarty, JI | 1 |
| Froeschl, M | 1 |
| Zarate, SB | 1 |
| Bahamonde Carrasco, A | 1 |
| Morán Blanco, A | 1 |
| Olcoz Goñi, JL | 1 |
| Morton, LD | 1 |
| Rizkallah, E | 1 |
| Dumoulin, A | 1 |
| Lapostolle, F | 1 |
| Adnet, F | 1 |
| Muzynski, J | 1 |
| Baud, FJ | 1 |
| Sajatovic, M | 1 |
| Gerhart, C | 1 |
| Semple, W | 1 |
| Dardennes, RM | 1 |
| Even, C | 1 |
| Matsumoto, J | 1 |
| Ogawa, H | 1 |
| Maeyama, R | 1 |
| Okudaira, K | 1 |
| Shinka, T | 1 |
| Kuhara, T | 1 |
| Matsumoto, I | 1 |
| Martinez, JM | 1 |
| Russell, JM | 2 |
| Lynch, A | 1 |
| Tobias, JD | 1 |
| Moreiras Plaza, M | 1 |
| Rodríguez Goyanes, G | 1 |
| Cuiña, L | 1 |
| Alonso, R | 1 |
| Grundy, S | 1 |
| Shelton, RC | 1 |
| Shulman, KI | 1 |
| Herrmann, N | 1 |
| Kline, MD | 1 |
| Jaggers, ED | 1 |
| Erfurth, A | 3 |
| Amann, B | 2 |
| Giupponi, G | 1 |
| Kammerer, C | 1 |
| Dilsaver, SC | 1 |
| Fecik, SE | 1 |
| Stoner, SC | 1 |
| Raphael, J | 1 |
| Lindsey, C | 1 |
| Motohashi, N | 1 |
| Catania, S | 1 |
| Cross, H | 1 |
| de Sousa, C | 1 |
| Boyd, S | 1 |
| Garno, JL | 1 |
| Leon, AC | 1 |
| Kocsis, JH | 2 |
| Portera, L | 1 |
| Marcuse, A | 1 |
| Normann, C | 1 |
| McEvoy, JP | 1 |
| Fayad, M | 1 |
| Choueiri, R | 1 |
| Mikati, M | 1 |
| Müller-Oerlinghausen, B | 1 |
| Retzow, A | 1 |
| Henn, FA | 1 |
| Giedke, H | 1 |
| Sacks, MH | 1 |
| Wassef, AA | 1 |
| Dott, SG | 1 |
| Harris, A | 1 |
| Brown, A | 1 |
| O'Boyle, M | 1 |
| Meyer, WJ | 1 |
| Rose, RM | 1 |
| Herbert, PB | 1 |
| Nelson, JC | 1 |
| Kowatch, RA | 1 |
| Carmody, TJ | 1 |
| Bucci, JP | 1 |
| Hume, JH | 1 |
| Kromelis, M | 1 |
| Emslie, GJ | 1 |
| Weinberg, WA | 1 |
| Chatham Showalter, PE | 1 |
| Kimmel, DN | 1 |
| Pollock, LM | 1 |
| Mitchell, SC | 1 |
| Mathew, NT | 1 |
| Kailasam, J | 1 |
| Meadors, L | 1 |
| Chernyschev, O | 1 |
| Gentry, P | 1 |
| Norton, J | 1 |
| Lerman-Sagie, T | 1 |
| Watemberg, N | 1 |
| Kramer, U | 1 |
| Lerman, P | 1 |
| Reeves, RR | 1 |
| Struve, FA | 1 |
| Patrick, G | 1 |
| Munhoz, RP | 1 |
| dos Santos, ML | 1 |
| Hernández-Fustes, OJ | 1 |
| Kottlors, M | 1 |
| Jaksch, M | 1 |
| Ketelsen, UP | 1 |
| Weiner, S | 1 |
| Glocker, FX | 1 |
| Lücking, CH | 1 |
| Lüttmann, RJ | 1 |
| Frese, A | 1 |
| Husstedt, IW | 1 |
| Evers, S | 1 |
| Chengappa, KN | 2 |
| Kupfer, DJ | 1 |
| Keeter, EL | 1 |
| Feldman, PD | 1 |
| Tollefson, GD | 1 |
| Breier, A | 2 |
| Shelton, MD | 1 |
| Rapport, DJ | 1 |
| Kujawa, M | 1 |
| Caban, S | 1 |
| Gershon, S | 1 |
| Milton, DR | 1 |
| Risser, R | 1 |
| Gilmore, JA | 1 |
| Tollefson, GA | 1 |
| Grossman, F | 1 |
| Okamoto, A | 1 |
| Batalden, PB | 1 |
| Van Dyne, BJ | 1 |
| Cloyd, J | 1 |
| Chadwick, DW | 1 |
| Cumming, WJ | 1 |
| Livingstone, I | 1 |
| Cartlidge, NE | 1 |
| Mimaya, H | 1 |
| Suchy, FJ | 1 |
| Balistreri, WF | 1 |
| Buchino, JJ | 1 |
| Sondheimer, JM | 1 |
| Bates, SR | 1 |
| Kearns, GL | 1 |
| Stull, JD | 1 |
| Bove, KE | 1 |
| Ozawa, Y | 1 |
| Inagaki, Y | 1 |
| Yonei, Y | 1 |
| Tsukada, N | 1 |
| Okawa, H | 1 |
| Kiryu, Y | 1 |
| Oda, M | 1 |
| Gerner, RH | 1 |
| Stanton, A | 1 |
| Kayemba Kay's Kabangu, S | 1 |
| Bovier Lapierre, M | 1 |
| Jalaguier, E | 1 |
| Rose, E | 1 |
| de Miscault, G | 1 |
| Thome, M | 1 |
| Boussard, N | 1 |
| Pope, HG | 2 |
| Hudson, JI | 2 |
| Morris, D | 1 |
| Post, RM | 1 |
| Denicoff, K | 1 |
| Weiss, SR | 1 |
| Roodhooft, AM | 1 |
| Van Dam, K | 1 |
| Haentjens, D | 1 |
| Verpooten, GA | 1 |
| Van Acker, KJ | 1 |
| Daoud, AS | 1 |
| Zaki, M | 1 |
| Shakir, R | 1 |
| al-Saleh, Q | 1 |
| Harendra de Silva, DG | 1 |
| Keembiyahetty, P | 1 |
| Jayantha, UK | 1 |
| Thelisinghe, PU | 1 |
| Badalian, LO | 1 |
| Berestov, AI | 1 |
| Blokhin, BM | 1 |
| Lidzhieva, RTs | 1 |
| Il'chuk, IT | 1 |
| Fawcett, J | 1 |
| McKee, RJ | 1 |
| Larkin, JG | 1 |
| Brodie, MJ | 1 |
| Legius, E | 1 |
| Jaeken, J | 1 |
| Eggermont, E | 1 |
| Coraggio, F | 1 |
| Angiulli, B | 1 |
| Carbone, M | 1 |
| Catalano, A | 1 |
| Costa, MR | 1 |
| Gargiulo, L | 1 |
| Gentile, B | 1 |
| Masetto, O | 1 |
| Pomponio, N | 1 |
| Scarpato, P | 1 |
| Rosenberg, HK | 1 |
| Ortega, W | 1 |
| Meerson, FZ | 1 |
| Shabunina, EV | 1 |
| Belkina, LM | 1 |
| Pshennikova, MG | 1 |
| Frifelt, JJ | 1 |
| Wanscher, MC | 1 |
| Wienholtz, G | 1 |
| Horwitz, N | 1 |
| Brockhattingen, A | 1 |
| Davion, T | 1 |
| Capron-Chivrac, D | 1 |
| Andrejak, M | 1 |
| Capron, JP | 1 |
| Dobrilla, G | 1 |
| Felder, M | 1 |
| Chilovi, F | 1 |
| Izumi, T | 1 |
| Utsumi, H | 1 |
| Osawa, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Endophenotype Characterization of a Family Psychiatric Disorder of the Bipolar Spectrum, With an Autosomal Dominant Expression[NCT02843997] | 29 participants (Anticipated) | Interventional | 2015-02-28 | Recruiting | |||
| Effect of Oxcarbazepine on Serum Brain Derived Neurotrophic Factor (BDNF) in Bipolar Disorder[NCT02456896] | Phase 4 | 50 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| Depakote ER in Bipolar Depression[NCT00186186] | Phase 4 | 28 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| An Inpatient Study of the Effectiveness and Safety of Depakote ER in the Treatment of Mania/Bipolar Disorder[NCT00060905] | Phase 3 | 370 participants | Interventional | 2003-01-31 | Completed | ||
| Efficacy and Tolerability of the Combination of LIthium and CArbamazepine Compared to Lithium and VALproic Acid in the Treatment of Young Bipolar Patients[NCT00976794] | Phase 4 | 40 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Six-Week, Double-Blind, Multicenter, Placebo Controlled Study Evaluating The Efficacy And Safety Of Flexible Doses Of Oral Ziprasidone As Add-On, Adjunctive Therapy With Lithium, Valproate Or Lamotrigine In Bipolar I Depression[NCT00483548] | Phase 3 | 298 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| A Phase 3, Placebo-Controlled, Double-Blinded Continuation Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Completing a 12-week Lead-in Trial and Continuing Lithium or Valproic Acid/Divalproex Sodium for the Treatment of an Acute Manic o[NCT00145509] | Phase 3 | 77 participants (Actual) | Interventional | 2005-08-31 | Completed | ||
| A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial Evaluating the Safety and Efficacy of Asenapine in Subjects Continuing Lithium or Valproic Acid/Divalproex Sodium for the Treatment of an Acute Manic or Mixed Episode[NCT00145470] | Phase 3 | 326 participants (Actual) | Interventional | 2005-06-02 | Completed | ||
| The Check Trial: A Comparison of Headache Treatment in the ED: Compazine Versus Ketamine. A Multi-Center, Randomized Double-Blind, Clinical Control Trial.[NCT02657031] | Phase 4 | 54 participants (Actual) | Interventional | 2016-03-17 | Completed | ||
| Intravenous Fluids in Benign Headaches Trail: A Randomized Single Blind Clinical Trial[NCT03185130] | Phase 4 | 58 participants (Actual) | Interventional | 2017-05-16 | Completed | ||
| Phase I Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma[NCT02761291] | Phase 1 | 18 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
| Phase 0 Clinical Trial With Valproic Acid as a Chemopreventive Agent in Patients With Head and Neck Squamous Cell Carcinoma Previously Treated[NCT02608736] | Early Phase 1 | 42 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| A Prophylactic Trial of Omega-3 Polyunsaturated Fatty Acids in Bipolar Disorder[NCT04210804] | Phase 2 | 80 participants (Actual) | Interventional | 2014-04-01 | Completed | ||
| Light-Therapy in the Treatment of the Acute Phase of the Bipolar Type II Depression: Double-Blind, Placebo-Controlled Study to Establish Efficacy and Safety[NCT00590265] | 50 participants (Anticipated) | Interventional | 2008-01-31 | Active, not recruiting | |||
| Phase 4 Study: Double-blind Placebo-controlled Trial of Depakote-ER for Depressive and Anxiety Symptoms in Non-refractory Bipolar Depression[NCT00226343] | Phase 4 | 25 participants | Interventional | 2003-08-31 | Completed | ||
| Imaging Framework for Testing GABAergic/Glutamatergic Drugs in Bipolar Alcoholics[NCT03220776] | Phase 2 | 54 participants (Actual) | Interventional | 2017-08-07 | Completed | ||
| The Safety And Efficacy Of Risperdal� (Risperidone) Versus Placebo Versus Haloperidol As Add-On Therapy To Mood Stabilizers In The Treatment Of The Manic Phase Of Bipolar Disorder[NCT00253149] | Phase 3 | 158 participants (Actual) | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Serum BDNF was estimated by ELISA using human BDNF ELISA kit from Boster Biological Technology Co. Ltd., Pleasanton, CA. (NCT02456896)
Timeframe: Baseline and 4 weeks
| Intervention | pg/ml (Mean) |
|---|---|
| Healthy Control | 23.1 |
| Oxcarbazepine | 90.7 |
"The YMRS total score ranges from 0 to 60 where higher scores indicate more severe mania.~Spearman's rank correlation coefficient (Spearman's ρ) was calculated for measuring correlation between YMRS score and serum BDNF." (NCT02456896)
Timeframe: At baseline
| Intervention | Spearman's ρ (Number) |
|---|---|
| Healthy Control | -0.59 |
| Oxcarbazepine | -0.59 |
"The Montgomery-Åsberg Depression Rating Scale (MADRS) is a ten-item diagnostic questionnaire which psychiatrists use to measure the severity of depressive episodes in patients with mood disorders.~Higher MADRS score indicates more severe depression the overall score ranges from 0 to 60.~Usual cutoff points are:~0 to 6 - normal/symptom absent 7 to 19 - mild depression 20 to 34 - moderate depression >34 - severe depression." (NCT00186186)
Timeframe: Baseline, 7 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Depakote ER | 14.9 |
A reduction greater than or equal to 50% in MADRS total score from baseline to the endpoint. (NCT00186186)
Timeframe: 7 weeks
| Intervention | participants (Number) |
|---|---|
| Depakote ER | 11 |
CGI-S is a single-item clinician rated scale used to assess global severity of bipolar illness based on an overall evaluation of symptoms of bipolar mania, associated behavioral symptoms, and condition of the subject. Scored from 1 (normal, not at all ill) to 7 (among the most severely ill subjects). Higher score = more affected. Change calculated as a difference between post-baseline observation and baseline CGI-S score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) |
|---|---|
| Ziprasidone | -1.5 |
| Placebo | -1.5 |
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). Change calculated as a difference between post-baseline observation and baseline MADRS score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) |
|---|---|
| Ziprasidone | -14.7 |
| Placebo | -13.2 |
Number of subjects with improvement defined as CGI-I response of 1 (very much improved) or 2 (much improved). CGI-I is a single-item clinician rated scale used to assess global improvement in the subject's clinical state (bipolar mania) in response to study treatment and as compared to their status at pre-treatment baseline. Scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse). Higher score = more affected. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | participants (Number) |
|---|---|
| Ziprasidone | 66 |
| Placebo | 69 |
Number of subjects with MADRS total score ≤ 12 (indicates remission). MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). (NCT00483548)
Timeframe: Week 6
| Intervention | participants (Number) |
|---|---|
| Ziprasidone | 48 |
| Placebo | 54 |
Number of subjects with reduction of ≥50 percent (%) in MADRS total score (indicates response). MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). Reduction calculated as ([A-B]/B*100): A=value at observation; B=baseline value. (NCT00483548)
Timeframe: Week 6
| Intervention | participants (Number) |
|---|---|
| Ziprasidone | 62 |
| Placebo | 65 |
CGI-I is a single-item clinician rated scale used to assess global improvement in the subject's clinical state (bipolar mania) in response to study treatment and as compared to their status at pre-treatment baseline. Scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse). Higher score = more affected. Week 6 is the primary timepoint. (NCT00483548)
Timeframe: Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=120, 138) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | Week 6 (n=92, 108) | |
| Placebo | 3.4 | 3.1 | 2.9 | 2.8 | 2.6 | 2.4 |
| Ziprasidone | 3.2 | 2.9 | 2.7 | 2.6 | 2.5 | 2.4 |
AIMS is a clinician rated 12-item scale to rate 7 body areas and global judgments on the severity of abnormal movements, incapacitation and subject's awareness of abnormal movements. Items 1 to 10 scored 0 (none) to 4 (severe); items 11 to 14 are No or Yes response to dental status and sleep movements and are assessed separately. AIMS total score is sum of first 7 items. Change calculated as a difference between post-baseline observation and baseline AIMS score values. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Total score: Week 2 (n=136, 142) | Total score: Week 4 (n=111, 127) | Total score: Week 6 (n=100, 111) | Global severity score: Week 2 (n=136, 142) | Global severity score: Week 4 (n=111, 127) | Global severity score: Week 6 (n=100, 111) | Incapacitation score: Week 2 (n=136, 142) | Incapacitation score: Week 4 (n=111, 127) | Incapacitation score: Week 6 (n=100, 111) | |
| Placebo | -0.1 | -0.0 | -0.0 | -0.0 | 0.0 | 0.0 | -0.0 | -0.0 | 0.0 |
| Ziprasidone | 0.1 | -0.0 | -0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
BARS is a clinician rated scale to evaluate akathisia associated with use of antipsychotic medications: objective motor restlessness, range 0 to 3; subjective complaints of restlessness and associated distress, range 0 to 3; global clinical assessment of akathisia, range 0 to 5. Higher scores indicate more affected. Change calculated as a difference between post-baseline observation and baseline BARS score values. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 2 (n=135, 139) | Week 4 (n=111, 125) | Week 6 (n=100, 110) | |
| Placebo | -0.0 | 0.0 | -0.0 |
| Ziprasidone | 0.1 | 0.0 | 0.0 |
CGI-S is a single-item clinician rated scale used to assess global severity of bipolar illness based on an overall evaluation of symptoms of bipolar mania, associated behavioral symptoms, and condition of the subject. Scores range from 1 (normal, not at all ill) to 7 (among the most severely ill subjects). Higher score = more affected. Change calculated as a difference between post-baseline observation and baseline CGI-S score values. (NCT00483548)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5
| Intervention | scores on scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=120, 139) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | |
| Placebo | -0.4 | -0.7 | -0.9 | -1.1 | -1.3 |
| Ziprasidone | -0.5 | -0.9 | -0.9 | -1.1 | -1.3 |
GAF is a clinician rated scale to measure the severity of illness-related impairment in psychological, social, and occupational functioning using a 100-point scale (single score of 1 to 100) with 100 indicating a superior level of function. Change calculated as a difference between post-baseline observation and baseline GAF score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) | |
|---|---|---|
| Week 6 (n=100, 110) | ET (n=34, 27) | |
| Placebo | 11.2 | 2.8 |
| Ziprasidone | 14.7 | 0.0 |
HAM-A is a clinician rated 14-item scale that rates the intensity of psychic anxiety (items 1 to 6 and item 14) and somatic anxiety (items 7 to 13) on a 5-point severity scale; scores range from 0 (not present) to 4 (very severe); lower score indicates less affected. Change calculated as a difference between post-baseline observation and baseline HAM-A score values. Week 6 is the primary timepoint. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 2 (n=136, 141) | Week 4 (n=111, 127) | Week 6 (n=100, 111) | |
| Placebo | -5.9 | -7.4 | -8.6 |
| Ziprasidone | -5.6 | -7.1 | -8.5 |
MADRS is a 10-item clinician rated scale to measure overall severity of depressive symptoms (apparent sadness, reported sadness, inner tension, reduced sleep, reduced appetite, concentration difficulties, lassitude, inability to feel, pessimistic thoughts, suicidal thoughts); rated on a 7-point Likert scale 0 (normal) to 6 (most abnormal); total score 0 to 44 (higher score indicates greater severity of symptoms). Change calculated as a difference between post-baseline observation and baseline MADRS score values. (NCT00483548)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5
| Intervention | scores on scale (Mean) | ||||
|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=121, 139) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | |
| Placebo | -6.1 | -9.0 | -11.0 | -11.8 | -13.3 |
| Ziprasidone | -8.1 | -11.7 | -13.0 | -14.1 | -14.9 |
Q-LES-Q is a 16-item subject rated scale to measure satisfaction with areas of daily functioning (physical health, social relationships, medication, and overall life satisfaction); rated on a 5-point Likert scale: higher scores indicate greater enjoyment and satisfaction with general life activities. Scores for items 1 to 14 are summed for a total score and converted to 0 to 100 range. Items 15 and 16 measure satisfaction with medication and overall satisfaction and are analyzed separately. Change calculated as a difference between post-baseline observation and baseline Q-LES-Q score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Total Q-LES-Q: Week 6 (n=82, 94) | Total Q-LES-Q: ET (n=27, 17) | Medications: Week 6 (n=91, 93) | Medications: ET (n=27, 20) | Overall life satisfaction: Week 6 (n=94, 103) | Overall life satisfaction: ET (n=31, 23) | |
| Placebo | 11.6 | 1.6 | 0.3 | -0.4 | 0.5 | 0.0 |
| Ziprasidone | 15.2 | -0.1 | 0.4 | -0.3 | 0.8 | 0.1 |
SDS is a 5-item subject rated scale to measure the extent to which work and or school, social life and or leisure activities, and home life and or family responsibilities were impaired by psychiatric illness. Items 1 to 3 rated on 11-point scale ranging 0 (not at all) to 10 (extremely affected). Total score 0 to 30; higher score indicates greater impairment; items 4 and 5 report number of days in the last month (0 to 31) subject missed work or school or was unproductive and are rated separately. Change calculated as a difference between post-baseline observation and baseline SDS score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | scores on scale (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Total SDS: Week 6 (n=58, 63) | Total SDS: ET (n=19, 14) | Work/School: Week 6 (n=58, 64) | Work/School: ET (n=19, 14) | Social life: Week 6 (n=94, 102) | Social life: ET (n=31, 23) | Family/Home: Week 6 (n=94, 102) | Family/Home: ET (n=31, 23) | |
| Placebo | -3.7 | -1.4 | -1.6 | -0.1 | -1.7 | 0.1 | -1.7 | -0.6 |
| Ziprasidone | -8.5 | 0.2 | -2.1 | 0.4 | -2.5 | -0.5 | -2.6 | 0.2 |
SDS is a 5-item subject rated scale to measure the extent to which work and or school, social life and or leisure activities, and home life and or family responsibilities were impaired by psychiatric illness. Items 1 to 3 rated on 11-point scale ranging 0 (not at all) to 10 (extremely affected). Total score 0 to 30; higher score indicates greater impairment; items 4 and 5 report number of days in the last month (0 to 31) subject missed work or school or was unproductive and are rated separately. Change calculated as a difference between post-baseline observation and baseline SDS score values. (NCT00483548)
Timeframe: Baseline, Week 6
| Intervention | days (Mean) | |||
|---|---|---|---|---|
| Days lost: Week 6 (n=85, 93) | Days lost: ET (n=29, 21) | Days unproductive: Week 6 (n=87, 89) | Days unproductive: ET (n=29, 21) | |
| Placebo | -0.7 | 0.0 | -1.3 | -0.1 |
| Ziprasidone | -1.2 | 0.5 | -1.6 | -0.2 |
SAS is a clinician rated 10-item scale to measure extrapyramidal side effects (Parkinsonism or Parkinsonian side effects induced with antipsychotics); rated on a 5-point scale with range 0 (absence of condition) to 4 (presence of condition in extreme form). Global score is sum of all scores divided by the total number of items. Change calculated as a difference between post-baseline observation and baseline SAS score values. (NCT00483548)
Timeframe: Baseline, Week 2, Week 4, Week 6
| Intervention | scores on scale (Mean) | ||
|---|---|---|---|
| Week 2 (n=136, 141) | Week 4 (n=111, 126) | Week 6 (n=100, 110) | |
| Placebo | -0.1 | 0.0 | -0.1 |
| Ziprasidone | 0.1 | 0.0 | 0.0 |
YMRS is clinician rated 11-item scale (elevated mood, increased motor activity-energy, sexual interest, sleep, irritability, speech [rate and amount], language-thought disorder, content, disruptive-aggressive behavior, appearance, and insight) used to assess the severity of manic symptoms and effect of treatment on mania severity. Seven items ranked on scale from 0 to 4; 4 items ranked 0 to 8. Higher scores indicate greater severity. Change calculated as a difference between post-baseline observation and baseline YMRS score values. Week 6 is the primary timepoint. (NCT00483548)
Timeframe: Baseline, Week 1, Week 2, Week 3, Week 4, Week 5, Week 6
| Intervention | scores on scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Week 1 (n=142, 141) | Week 2 (n=121, 139) | Week 3 (n=115, 130) | Week 4 (n=106, 122) | Week 5 (n=103, 112) | Week 6 (n=92, 108) | |
| Placebo | -0.2 | -0.2 | -0.2 | -1.1 | -1.3 | -0.9 |
| Ziprasidone | 0.7 | 0.5 | -0.0 | -0.9 | -0.9 | -1.0 |
The MADRS is a 10-item clinician-rated scale for assessing the severity of symptoms of depression. MADRS total score range = 0-60; higher scores indicate greater severity of symptoms. (NCT00145509)
Timeframe: Baseline and 52 Weeks
| Intervention | Score on a scale (Mean) |
|---|---|
| Asenapine | -3.3 |
| Placebo | -3.9 |
The Y-MRS is an 11-item, clinician-rated instrument used for assessing the symptoms of mania. Y-MRS total score range = 0-60; higher scores indicate greater severity of symptoms. (NCT00145509)
Timeframe: Baseline and 52 Weeks
| Intervention | Score on a Scale (Mean) |
|---|---|
| Asenapine | -17.2 |
| Placebo | -19.7 |
Participants who discontinued study medication due to adverse events. (NCT00145509)
Timeframe: 40 weeks
| Intervention | participants (Number) |
|---|---|
| Asenapine | 10 |
| Placebo | 3 |
Participants who experienced treatment-emergent adverse events, defined as adverse events reported on or after the first dose of study medication in the 12-week lead-in study through the last dose of study drug + 7 days (or + 30 days for serious adverse events). (NCT00145509)
Timeframe: up to 52 weeks
| Intervention | Participants (Number) |
|---|---|
| Asenapine | 32 |
| Placebo | 25 |
The number of participants discontinuing study treatment due to an AE was assessed. An AE is any untoward or unfavorable medical occurrence in a participant, including any abnormal sign, symptom, or disease, temporally associated with the use of the investigational product, whether or not considered related to the investigational product. (NCT00145470)
Timeframe: Up to Day 84
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 18 |
| Asenapine | 25 |
The number of participants experiencing an AE was assessed. An AE is any untoward or unfavorable medical occurrence in a participant, including any abnormal sign, symptom, or disease, temporally associated with the use of the investigational product, whether or not considered related to the investigational product. (NCT00145470)
Timeframe: Up to Day 114
| Intervention | Participants (Count of Participants) |
|---|---|
| Placebo | 114 |
| Asenapine | 116 |
"The percentage of participants determined to be ready to discharge at day 84 was estimated (Kaplan-Meier), using the readiness to discharge questionnaire (RDQ). The RDQ is clinician-rated scale to assess readiness for discharge, composed of 7 items. Of the 7 items, only the first 5 items were utilized:~Not actively suicidal/homicidal;~Adequate control over aggression and impulsivity;~Able to carry out basic activities of daily life;~Able to take medicine independently; and~Delusions and hallucinations do not significantly interfere with functioning.~For the 5 items, the clinician provided a response (Strongly Disagree; Disagree; Agree; or Strongly Agree) at each pre-specified visit. The first visit at which the responses to the first 5 items on the RDQ are Strongly Agree or Agree, was defined as the point a participant was ready to discharge." (NCT00145470)
Timeframe: Day 84
| Intervention | Percentage of Participants (Number) |
|---|---|
| Placebo | 74.1 |
| Asenapine | 89.7 |
Least squares mean change from baseline at day 21 in quality of life was assessed, as determined by SF-36v2. The SF-36v2 is a self-administered questionnaire, measuring 8 domains: Physical Functioning (PF); Role-Physical (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role-Emotional (RE); and Mental Health (MH). These 8 concepts are further organized into a Physical Component Summary (PCS; composite of PF, RP, BP, and GH) and a Mental Component Summary (MCS; composite of VT, SF, RE, and MH). The SF-36v2 domains and composite summaries were scored using a norm-based scoring approach, yielding a mean of 50 and standard deviation of 10 based on the norms from the 1998 SF-36 United States general population norms. For the PCS and MCS, scores range from 0 to 100, with higher scores indicating better quality of life. Further, decreases in quality of life (by PCS and MCS) are reflected by a negative change from baseline. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |||
|---|---|---|---|---|
| PCS - Baseline | PCS - Change from Baseline at Day 21 | MCS - Baseline | MCS - Change from Baseline at Day 21 | |
| Asenapine | 51.64 | -2.47 | 39.03 | 5.93 |
| Placebo | 50.49 | -0.72 | 40.83 | 2.29 |
Least squares mean change from baseline at day 84 in quality of life was assessed, as determined by SF-36v2. The SF-36v2 is a self-administered questionnaire, measuring 8 domains: Physical Functioning (PF); Role-Physical (RP); Bodily Pain (BP); General Health (GH); Vitality (VT); Social Functioning (SF); Role-Emotional (RE); and Mental Health (MH). These 8 concepts are further organized into a Physical Component Summary (PCS; composite of PF, RP, BP, and GH) and a Mental Component Summary (MCS; composite of VT, SF, RE, and MH). The SF-36v2 domains and composite summaries were scored using a norm-based scoring approach, yielding a mean of 50 and standard deviation of 10 based on the norms from the 1998 SF-36 United States general population norms. For the PCS and MCS, scores range from 0 to 100, with higher scores indicating better quality of life. Further, decreases in quality of life (by PCS and MCS) are reflected by a negative change from baseline. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |||
|---|---|---|---|---|
| PCS - Baseline | PCS - Change from Baseline at Day 84 | MCS - Baseline | MCS - Change from Baseline at Day 84 | |
| Asenapine | 51.64 | -0.95 | 39.03 | 2.49 |
| Placebo | 50.49 | 1.37 | 40.83 | -1.05 |
The least squares mean change from baseline in CGI-BP severity of depression score at day 21 was assessed. The CGI-BP severity of depression scale is a clinician-rated scale for assessing the severity of depressive symptoms of bipolar disorder, with scores ranging from 1 (normal) to 7 (very severely ill). Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 2.3 | -0.2 |
| Placebo | 2.3 | -0.1 |
The least squares mean change from baseline in CGI-BP severity of depression score at day 84 was assessed. The CGI-BP severity of depression scale is a clinician-rated scale for assessing the severity of depressive symptoms of bipolar disorder, with scores ranging from 1 (normal) to 7 (very severely ill). Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 2.3 | -0.1 |
| Placebo | 2.3 | -0.1 |
The least squares mean change from baseline in CGI-BP severity of mania score at day 21 was assessed. The CGI-BP severity of mania scale is a clinician-rated scale for assessing the severity of manic symptoms of bipolar disorder, with scores ranging from 1 (normal) to 7 (very severely ill). Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 4.5 | -1.1 |
| Placebo | 4.5 | -0.8 |
The least squares mean change from baseline in CGI-BP severity of mania score at day 84 was assessed. The CGI-BP severity of mania scale is a clinician-rated scale for assessing the severity of manic symptoms of bipolar disorder, with scores ranging from 1 (normal) to 7 (very severely ill). Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 4.5 | -1.5 |
| Placebo | 4.5 | -1.0 |
The least squares mean change from baseline in CGI-BP severity of severity of overall bipolar illness score at day 21 was assessed. The CGI-BP severity of overall bipolar illness scale is a clinician-rated scale for assessing the severity of overall symptoms of bipolar disorder, with scores ranging from 1 (normal) to 7 (very severely ill). Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 4.6 | -1.0 |
| Placebo | 4.6 | -0.7 |
The least squares mean change from baseline in CGI-BP severity of severity of overall bipolar illness score at day 84 was assessed. The CGI-BP severity of overall bipolar illness scale is a clinician-rated scale for assessing the severity of overall symptoms of bipolar disorder, with scores ranging from 1 (normal) to 7 (very severely ill). Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 4.6 | -1.2 |
| Placebo | 4.6 | -0.8 |
The least squares mean change from baseline in HAM-A score at day 21 was assessed. The HAM-A is a clinician-rated instrument for assessing anxiety symptoms, composed of 14 items. For the 14 items, scores range from 0 (not present) to 4 (severe). Scores for individual items add to a total score (range: 0-56), with higher scores indicating greater severity of anxiety. Further, decreases in anxiety severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 8.8 | -2.4 |
| Placebo | 9.3 | -2.1 |
The least squares mean change from baseline in HAM-A score at day 84 was assessed. The HAM-A is a clinician-rated instrument for assessing anxiety symptoms, composed of 14 items. For the 14 items, scores range from 0 (not present) to 4 (severe). Scores for individual items add to a total score (range: 0-56), with higher scores indicating greater severity of anxiety. Further, decreases in anxiety severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 8.8 | -2.1 |
| Placebo | 9.3 | -2.1 |
The least squares mean change from baseline in ISST-Modified score at day 21 was assessed. The ISST-Modified is a clinician-rated scale for rating suicidality, composed of 12 items (score range: 0-2). Scores for the 12 items add to a total ISST-Modified score (range: 0-24), with higher scores indicating increased severity of suicidal thinking. Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 0.4 | 0.0 |
| Placebo | 0.6 | -0.0 |
The least squares mean change from baseline in ISST-Modified score at day 84 was assessed. The ISST-Modified is a clinician-rated scale for rating suicidality, composed of 12 items (score range: 0-2). Scores for the 12 items add to a total ISST-Modified score (range: 0-24), with higher scores indicating increased severity of suicidal thinking. Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 0.4 | 0.3 |
| Placebo | 0.6 | -0.0 |
The least squares mean change from baseline in MADRS score at day 21 was assessed. The MARDS is a clinician-rated scale for assessing the severity of symptoms of depression, composed of 10 items. For the 10 items, scores range from 0 (symptoms absent) to 6 (severe). Scores for individual items add to a total score (range: 0-60), with higher scores indicating greater severity of depression. Further, decreases in depression severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 11.3 | -2.9 |
| Placebo | 11.4 | -2.2 |
The least squares mean change from baseline in MADRS score at day 84 was assessed. The MARDS is a clinician-rated scale for assessing the severity of symptoms of depression, composed of 10 items. For the 10 items, scores range from 0 (symptoms absent) to 6 (severe). Scores for individual items add to a total score (range: 0-60), with higher scores indicating greater severity of depression. Further, decreases in depression severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 11.3 | -1.6 |
| Placebo | 11.4 | -1.7 |
The least squares mean change from baseline in PANSS score at day 21 was assessed. The PANSS assesses the severity of schizophrenia symptoms through a clinician-rated inventory of 30 items organized in 3 subscales: 1) positive subscale (7 items); 2) negative subscale (7 items); and 3) general psychopathology subscale (16 items). For each item, symptoms are scored from 1 (absent) to 7 (extreme) and add to a total PANSS score (range: 30-210). Higher scores reflect more severe symptoms of schizophrenia. Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 65.1 | -7.2 |
| Placebo | 67.1 | -5.4 |
The least squares mean change from baseline in PANSS score at day 84 was assessed. The PANSS assesses the severity of schizophrenia symptoms through a clinician-rated inventory of 30 items organized in 3 subscales: 1) positive subscale (7 items); 2) negative subscale (7 items); and 3) general psychopathology subscale (16 items). For each item, symptoms are scored from 1 (absent) to 7 (extreme) and add to a total PANSS score (range: 30-210). Higher scores reflect more severe symptoms of schizophrenia. Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 65.1 | -7.4 |
| Placebo | 67.1 | -6.0 |
The least squares mean change from baseline in Q-LES-Q score at day 21 was assessed. The Q-LES-Q is a participant-completed questionnaire to assess general satisfaction with activities such as physical health, mood, work, household tasks, social and family relationships, leisure activities, and overall satisfaction, composed of 16 items. For each of the 16 items, scores range from 0 (very poor) to 5 (very good), with scores for all items adding to a total score (range: 0-80); higher scores indicate better quality of life. Further, decreases in quality of life are reflected by a negative change from baseline. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 61.3 | 4.6 |
| Placebo | 61.0 | 3.9 |
The least squares mean change from baseline in Q-LES-Q score at day 84 was assessed. The Q-LES-Q is a participant-completed questionnaire to assess general satisfaction with activities such as physical health, mood, work, household tasks, social and family relationships, leisure activities, and overall satisfaction, composed of 16 items. For each of the 16 items, scores range from 0 (very poor) to 5 (very good), with scores for all items adding to a total score (range: 0-80); higher scores indicate better quality of life. Further, decreases in quality of life are reflected by a negative change from baseline. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 61.3 | -1.1 |
| Placebo | 61.0 | -3.7 |
The least squares mean change from baseline in Y-MRS score at day 21 was assessed. The Y-MRS is a clinician-rated instrument used for assessing the symptoms of mania, composed of 11 items. For the 11 items, scores range from 0 (symptoms absent) to, depending on the item, either 4 (7 items) or 8 (4 items). Scores for individual items add to a total score (range: 0-60), with higher scores indicating greater symptom severity. Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a last observation carried forward (LOCF) analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 21 | |
| Asenapine | 27.9 | -10.3 |
| Placebo | 28.2 | -7.9 |
The least squares mean change from baseline in Y-MRS score at day 42 was assessed. The Y-MRS is a clinician-rated instrument used for assessing the symptoms of mania, composed of 11 items. For the 11 items, scores range from 0 (symptoms absent) to, depending on the item, either 4 (7 items) or 8 (4 items). Scores for individual items add to a total score (range: 0-60), with higher scores indicating greater symptom severity. Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 42
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 42 | |
| Asenapine | 27.9 | -11.4 |
| Placebo | 28.2 | -8.7 |
The least squares mean change from baseline in Y-MRS score at day 84 was assessed. The Y-MRS is a clinician-rated instrument used for assessing the symptoms of mania, composed of 11 items. For the 11 items, scores range from 0 (symptoms absent) to, depending on the item, either 4 (7 items) or 8 (4 items). Scores for individual items add to a total score (range: 0-60), with higher scores indicating greater symptom severity. Further, decreases in symptom severity over time would be reflected by negative changes from baseline. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Least Squares Mean) | |
|---|---|---|
| Baseline | Change from Baseline at Day 84 | |
| Asenapine | 27.9 | -12.7 |
| Placebo | 28.2 | -9.3 |
"Nine neurocognitive tests with higher scores indicating better performance:~Verbal Memory test: recognize/remember/retrieve words (range 0-60)~Visual Memory test: recognize/remember/retrieve geometric figures (range 0-60)~Speed of Processing: recognize/process information. No min./max. score. Normative average (NA); correct answers: 65.1, avg. errors: 1.37~Social Acuity/Perception of Emotions test: perceive/respond to emotional cues. Min. score: -64/Max. score: 16~Reasoning: reason/respond to non-verbal, visual-abstract stimuli; scores range: -15 to 15~Executive Function: recognize rules/categories/decision making. No min./max. score. NA correct answers: 55.01/avg. errors: 5.28~Working Memory/Continuous Performance Task (CPT): perceive/attend to symbols. Min. score: -45/Max. score: 15~Sustained Attention: direct/focus on specific stimuli: Max. score (raw score); 45; Min. score: -170~Composite Memory: working+verbal+visual memory, Range 0-135." (NCT00145470)
Timeframe: Baseline and Day 21
| Intervention | Score on a Scale (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verbal Memory - Baseline | Visual Memory - Baseline | Processing Speed - Baseline | Social Acuity - Baseline | Reasoning - Baseline | Executive Functioning - Baseline | Working Memory - Baseline | Sustained Attention - Baseline | Composite Memory - Baseline | Verbal Memory - CFB at Day 21 | Visual Memory - CFB at Day 21 | Processing Speed - CFB at Day 21 | Social Acuity - CFB at Day 21 | Reasoning - CFB at Day 21 | Executive Functioning - CFB at Day 21 | Working Memory - CFB at Day 21 | Sustained Attention - CFB at Day 21 | Composite Memory - CFB at Day 21 | |
| Asenapine | 44.6 | 38.2 | 39.5 | 2.7 | 1.3 | 16.9 | 2.9 | 13.5 | 82.8 | 0.8 | -0.4 | 4.2 | 0.3 | 0.7 | 10.1 | -0.4 | -0.8 | 0.5 |
| Placebo | 43.6 | 38.0 | 34.3 | 2.8 | 2.1 | 17.6 | 2.9 | 14.0 | 81.6 | -0.8 | -0.3 | 3.8 | 1.0 | 0.3 | 4.4 | 0.2 | 0.3 | -1.1 |
"Nine neurocognitive tests with higher scores indicating better performance:~Verbal Memory test: recognize/remember/retrieve words (range 0-60)~Visual Memory test: recognize/remember/retrieve geometric figures (range 0-60)~Speed of Processing: recognize/process information. No min./max. score. Normative average (NA); correct answers: 65.1, avg. errors: 1.37~Social Acuity/Perception of Emotions test: perceive/respond to emotional cues. Min. score: -64/Max. score: 16~Reasoning: reason/respond to non-verbal, visual-abstract stimuli; scores range: -15 to 15~Executive Function: recognize rules/categories/decision making. No min./max. score. NA correct answers: 55.01/avg. errors: 5.28~Working Memory/Continuous Performance Task (CPT): perceive/attend to symbols. Min. score: -45/Max. score: 15~Sustained Attention: direct/focus on specific stimuli: Max. score (raw score); 45; Min. score: -170~Composite Memory: working+verbal+visual memory, Range 0-135." (NCT00145470)
Timeframe: Baseline and Day 84
| Intervention | Score on a Scale (Mean) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Verbal Memory - Baseline | Visual Memory - Baseline | Processing Speed - Baseline | Social Acuity - Baseline | Reasoning - Baseline | Executive Functioning - Baseline | Working Memory - Baseline | Sustained Attention - Baseline | Composite Memory - Baseline | Verbal Memory - CFB at Day 84 | Visual Memory - CFB at Day 84 | Processing Speed - CFB at Day 84 | Social Acuity - CFB at Day 84 | Reasoning - CFB at Day 84 | Executive Functioning - CFB at Day 84 | Working Memory - CFB at Day 84 | Sustained Attention - CFB at Day 84 | Composite Memory - CFB at Day 84 | |
| Asenapine | 44.6 | 38.2 | 39.5 | 2.7 | 1.3 | 16.9 | 2.9 | 13.5 | 82.8 | -0.3 | -0.5 | -1.4 | 0.9 | 1.0 | 10.2 | -0.4 | 0.5 | -0.7 |
| Placebo | 43.6 | 38.0 | 34.3 | 2.8 | 2.1 | 17.6 | 2.9 | 14.0 | 81.6 | -0.0 | 0.0 | 3.6 | 0.7 | -0.1 | 3.9 | -0.2 | -0.5 | -0.0 |
The Y-MRS is a clinician-rated instrument used for assessing the symptoms of mania, composed of 11 items. For the 11 items, scores range from 0 (symptoms absent) to, depending on the item, either 4 (7 items) or 8 (4 items). Scores for individual items add to a total score (range: 0-60), with higher scores indicating greater symptom severity. At pre-specified time points, the number of participants achieving Y-MRS remitter status was assessed, defined as the number of participants with a Y-MRS total score of 12 or lower. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Up to Day 84
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Day 3 | Day 7 | Day 14 | Day 21 | Day 42 | Day 63 | Day 84 | |
| Asenapine | 11 | 19 | 42 | 52 | 64 | 63 | 67 |
| Placebo | 8 | 21 | 32 | 35 | 46 | 46 | 49 |
The Y-MRS is a clinician-rated instrument used for assessing the symptoms of mania, composed of 11 items. For the 11 items, scores range from 0 (symptoms absent) to, depending on the item, either 4 (7 items) or 8 (4 items). Scores for individual items add to a total score (range: 0-60), with higher scores indicating greater symptom severity. At pre-specified time points, the number of participants achieving Y-MRS responder status was assessed, defined as the number of participants with a 50% decrease from baseline in Y-MRS total score. For evaluation of this endpoint, a LOCF analysis was used; baseline values are not eligible to be carried forward to missing post-baseline assessments. (NCT00145470)
Timeframe: Up to Day 84
| Intervention | Participants (Count of Participants) | ||||||
|---|---|---|---|---|---|---|---|
| Day 3 | Day 7 | Day 14 | Day 21 | Day 42 | Day 63 | Day 84 | |
| Asenapine | 13 | 22 | 46 | 53 | 67 | 66 | 74 |
| Placebo | 10 | 25 | 34 | 44 | 52 | 52 | 56 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum anxiety. A change of 0 mm corresponds to no change in anxiety level, and a negative value indicates worsening of the anxiety after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 33.7 |
| Study Arm | 21.2 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. Positive values represent a reduction in headache severity. The maximum possible change in VAS score is 100 mm, representing the complete relief of a maximally severe headache. A change of 0 mm corresponds to no change in headache severity, and a negative value indicates worsening of the headache after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 63.5 |
| Study Arm | 43.5 |
Reduction in 100 mm Visual Analog Scale (VAS) Score. The maximum possible change in VAS score is 100 mm, representing the complete relief of maximum nausea. A change of 0 mm corresponds to no change in nausea level, and a negative value indicates worsening of the nausea after the medication. (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | mm (Mean) |
|---|---|
| Control Arm | 38.9 |
| Study Arm | 22.9 |
Yes/No (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | participants (Number) |
|---|---|
| Control Arm | 2 |
| Study Arm | 3 |
Yes/No (NCT02657031)
Timeframe: 0-60 minutes
| Intervention | participants (Number) |
|---|---|
| Control Arm | 3 |
| Study Arm | 3 |
Concentrations of GABA+, referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy (i.e., MEGA-PRESS). (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 3.90 |
| Gabapentin | 3.93 |
| Placebo Oral Tablet | 3.73 |
Concentrations of Glx (i.e., glutamate + glutamine), referenced to unsuppressed water and corrected for within-voxel CSF proportion, in dorsal anterior cingulate cortex measured via Proton Magnetic Resonance Spectroscopy. (NCT03220776)
Timeframe: Day 5 of each experimental condition
| Intervention | mmol/kg (Mean) |
|---|---|
| N-Acetylcysteine | 21.59 |
| Gabapentin | 21.69 |
| Placebo Oral Tablet | 22.25 |
52 reviews available for valproic acid and Acute Disease
| Article | Year |
|---|---|
Lithium for acute mania.
Topics: Acute Disease; Antipsychotic Agents; Bipolar Disorder; Humans; Lithium Compounds; Randomized Control | 2019 |
Valproic acid-induced acute pancreatitis and multiorgan failure in a child.
Topics: Abdominal Pain; Acute Disease; Anticonvulsants; Child; Delayed Diagnosis; Diagnostic Errors; Dissemi | 2013 |
Absence seizures in children.
Topics: Acute Disease; Anticonvulsants; Child; Epilepsy, Absence; Ethosuximide; Evidence-Based Medicine; Hum | 2013 |
Comparative efficacy and acceptability of combined antipsychotics and mood stabilizers versus individual drug classes for acute mania: Network meta-analysis.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Double-Blind | 2015 |
Monotherapy versus combined treatment with second-generation antipsychotics in bipolar disorder.
Topics: Acute Disease; Affect; Anticonvulsants; Antidepressive Agents; Antimanic Agents; Antipsychotic Agent | 2008 |
Absence seizures in children.
Topics: Acute Disease; Anticonvulsants; Child; Epilepsy, Absence; Ethosuximide; Evidence-Based Medicine; Hum | 2008 |
Extracorporeal elimination in acute valproic acid poisoning.
Topics: Acute Disease; Anticonvulsants; Databases, Bibliographic; Drug Overdose; Half-Life; Hemoperfusion; H | 2009 |
Valproate for the treatment of acute bipolar depression: systematic review and meta-analysis.
Topics: Acute Disease; Affect; Anticonvulsants; Bipolar Disorder; Humans; Randomized Controlled Trials as To | 2010 |
Divalproex sodium versus placebo in the treatment of acute bipolar depression: a systematic review and meta-analysis.
Topics: Acute Disease; Anticonvulsants; Bipolar Disorder; Humans; Randomized Controlled Trials as Topic; Tre | 2010 |
Mixed episodes with psychotic features.
Topics: Acute Disease; Adult; Affect; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; | 2009 |
Oxcarbazepine for acute affective episodes in bipolar disorder.
Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Carbamazepine; Child; Humans; | 2011 |
Treatment of agitation in bipolar disorder across the life cycle.
Topics: Acute Disease; Adolescent; Adult; Age Factors; Age of Onset; Anticonvulsants; Antipsychotic Agents; | 2003 |
Treating acute mania.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Humans; Li | 2003 |
Optimal dosing of medications (in bipolar disorder).
Topics: Acute Disease; Affect; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Ch | 2003 |
Acute pancreatitis in children from Valproic acid: case series and review.
Topics: Acute Disease; Adolescent; Anticonvulsants; Child; Child, Preschool; Epilepsy; Fatal Outcome; Female | 2003 |
Acute management of seizures in the syndromes of idiopathic generalized epilepsies.
Topics: Acute Disease; Adolescent; Adult; Anticonvulsants; Clonazepam; Comorbidity; Drug Administration Sche | 2003 |
The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dia | 2003 |
[Treatment of acute bipolar disorder. Intriguing balancing act between mania and depression].
Topics: Acute Disease; Algorithms; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Benzodiaze | 2003 |
Bipolar depression: an overview.
Topics: Acute Disease; Antidepressive Agents; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Chemoprev | 2004 |
Separate and concomitant use of lamotrigine, lithium, and divalproex in bipolar disorders.
Topics: Acute Disease; Administration, Oral; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; | 2004 |
Atypical antipsychotic augmentation of mood stabilizer therapy in bipolar disorder.
Topics: Acute Disease; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Clinical Trials as Topic; De | 2005 |
Lamotrigine and antiepileptic drugs as mood stabilizers in bipolar disorder.
Topics: Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Cyclohexa | 2005 |
Pancreatitis, complicated by a pancreatic pseudocyst associated with the use of valproic acid.
Topics: Acute Disease; Anticonvulsants; Child; Epilepsy; Humans; Male; Pancreatic Pseudocyst; Pancreatitis; | 2005 |
Linear relationship of valproate serum concentration to response and optimal serum levels for acute mania.
Topics: Acute Disease; Adult; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Dose-Response Relati | 2006 |
Targeting epigenetic changes in acute myeloid leukemia.
Topics: Acetylation; Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Depsipeptide | 2005 |
Acute treatment of mania: an update on new medications.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Approval; Drug Therapy | 2006 |
[Clinical standing of valproate treatment of bipolar disorders].
Topics: Acute Disease; Antimanic Agents; Bipolar Disorder; Depression; Drug Therapy, Combination; Humans; Lo | 2007 |
Quetiapine for acute mania in bipolar disorder.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Drug In | 2007 |
Valproic acid for the treatment of myeloid malignancies.
Topics: Acute Disease; Apoptosis; Cell Line, Tumor; Drug Synergism; Drug Therapy, Combination; Histone Deace | 2007 |
Adjunctive treatment of acute mania: a clinical overview.
Topics: Acute Disease; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Thera | 2007 |
GABAergic drugs for the treatment of migraine.
Topics: Acute Disease; Amines; Animals; Cyclohexanecarboxylic Acids; Fructose; GABA Agents; GABA Antagonists | 2007 |
Use of intravenous valproic acid for acute migraine.
Topics: Acute Disease; Clinical Trials as Topic; Humans; Injections, Intravenous; Migraine Disorders; Valpro | 2008 |
Fatal acute pancreatitis caused by valproic acid.
Topics: Acute Disease; Adult; Cerebral Palsy; Fatal Outcome; Female; Humans; Pancreatitis; Seizures; Valproi | 1995 |
[A case of acute pancreatitis during administration of valproic acid].
Topics: Acute Disease; Adolescent; Epilepsy; Humans; Male; Pancreatitis; Valproic Acid | 1993 |
Bipolar mood disorder: practical strategies for acute and maintenance phase treatment.
Topics: Acute Disease; Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Clinical T | 1996 |
[Acute pancreatitis caused by valproic acid: apropos a case].
Topics: Acute Disease; Adolescent; Anticonvulsants; Drug Therapy, Combination; Humans; Male; Pancreatitis; V | 1996 |
New drug therapy for acute seizure management.
Topics: Acute Disease; Anticonvulsants; Child; Diazepam; Epilepsy; Humans; Phenytoin; Prodrugs; Seizures; Va | 1997 |
Key treatment studies of lithium in manic-depressive illness: efficacy and side effects.
Topics: Acute Disease; Bipolar Disorder; Clinical Trials as Topic; Delayed-Action Preparations; Drug Adminis | 1998 |
Management of acute mania.
Topics: Acute Disease; Algorithms; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; | 1999 |
Mood-stabilizing drugs in depression.
Topics: Acute Disease; Anticonvulsants; Antidepressive Agents, Tricyclic; Antipsychotic Agents; Bipolar Diso | 1999 |
Bipolar disorder in old age.
Topics: Acute Disease; Adult; Age Factors; Aged; AIDS Dementia Complex; Antidepressive Agents; Antimanic Age | 1999 |
Algorithms for the pharmacotherapy of bipolar disorder.
Topics: Acute Disease; Algorithms; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug Therapy, Combinat | 1999 |
New treatments for bipolar disorder: the role of atypical neuroleptic agents.
Topics: Acute Disease; Algorithms; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazep | 2000 |
Current research on rapid cycling bipolar disorder and its treatment.
Topics: Acute Disease; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug Administration Schedule; Drug | 2001 |
The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder.
Topics: Acetates; Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2001 |
[Acute pancreatitis and valproic acid].
Topics: Acute Disease; Child; Epilepsy; Humans; Male; Pancreatitis; Valproic Acid | 1991 |
[Acute pancreatitis caused by sodium valproate. Review of the literature apropos of a case in a child].
Topics: Acute Disease; Child; Humans; Male; Pancreatitis; Prognosis; Valproic Acid | 1991 |
Antiepileptic drugs in affective illness. Clinical and theoretical implications.
Topics: Acute Disease; Anticonvulsants; Benzodiazepines; Bipolar Disorder; Carbamazepine; Depression; Drug T | 1991 |
[Reye's syndrome in children (review of the literature)].
Topics: Acute Disease; Child; Child, Preschool; Humans; Infant; Infant, Newborn; Respiratory Tract Infection | 1990 |
Valproate use in acute mania and bipolar disorder: an international perspective.
Topics: Acute Disease; Bipolar Disorder; Clinical Trials as Topic; Europe; Humans; Valproic Acid | 1989 |
[Acute hepatic steatosis. Description of a clinical case of sodium valproate-induced acute hepatic steatosis].
Topics: Acute Disease; Adult; Biopsy; Child; Child, Preschool; Diagnosis, Differential; Fatty Liver; Fatty L | 1988 |
[Hepatitis due to antiepileptic agents].
Topics: Acute Disease; Anticonvulsants; Barbiturates; Benzodiazepines; Carbamazepine; Chemical and Drug Indu | 1985 |
60 trials available for valproic acid and Acute Disease
| Article | Year |
|---|---|
Protocol for seizure prophylaxis following intracerebral hemorrhage study (SPICH): a randomized, double-blind, placebo-controlled trial of short-term sodium valproate prophylaxis in patients with acute spontaneous supratentorial intracerebral hemorrhage.
Topics: Acute Disease; Anticonvulsants; Cerebral Hemorrhage; China; Clinical Protocols; Double-Blind Method; | 2014 |
Effect of intravenous sodium valproate vs dexamethasone on acute migraine headache: a double blind randomized clinical trial.
Topics: Acute Disease; Administration, Intravenous; Adult; Chi-Square Distribution; Dexamethasone; Double-Bl | 2015 |
Treatment of status epilepticus and acute repetitive seizures with i.v. valproic acid vs phenytoin.
Topics: Acute Disease; Adult; Aged; Anticonvulsants; Brain; Drug-Related Side Effects and Adverse Reactions; | 2008 |
Comparative efficacy and safety of oxcarbazepine versus divalproex sodium in the treatment of acute mania: a pilot study.
Topics: Acute Disease; Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Double-Bli | 2009 |
A randomized, placebo-controlled, multicenter study of divalproex sodium extended-release in the acute treatment of mania.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Delayed-Action Preparati | 2010 |
LICAVAL: combination therapy in acute and maintenance treatment of bipolar disorder.
Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Carbamazepine; Cognition; Drug | 2010 |
Efficacy and safety of adjunctive oral ziprasidone for acute treatment of depression in patients with bipolar I disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Bipolar Disorder; Depressive Disorder, Maj | 2011 |
Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.
Topics: Acute Disease; Adult; Affect; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disor | 2012 |
Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.
Topics: Acute Disease; Adult; Affect; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disor | 2012 |
Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.
Topics: Acute Disease; Adult; Affect; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disor | 2012 |
Asenapine as adjunctive treatment for acute mania associated with bipolar disorder: results of a 12-week core study and 40-week extension.
Topics: Acute Disease; Adult; Affect; Anticonvulsants; Antimanic Agents; Antipsychotic Agents; Bipolar Disor | 2012 |
Efficacy and safety of combination of risperidone and haloperidol with divalproate in patients with acute mania.
Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Body Wei | 2012 |
A randomized open-label study of sodium valproate vs sumatriptan and metoclopramide for prolonged migraine headache.
Topics: Acute Disease; Adult; Analgesics; Dopamine Antagonists; Drug Therapy, Combination; Female; GABA Agen | 2013 |
A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania.
Topics: Acute Disease; Adolescent; Analysis of Variance; Antimanic Agents; Bipolar Disorder; Child; Dibenzot | 2002 |
A pilot study of loading versus titration of valproate in the treatment of acute mania.
Topics: Acute Disease; Adolescent; Adult; Aged; Antidepressive Agents; Bipolar Disorder; Diagnostic and Stat | 2002 |
Initial triple therapy of acute mania, adding lithium and valproate to neuroleptics.
Topics: Acute Disease; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Drug Therapy, | 2002 |
Initial lithium and valproate combination therapy in acute mania.
Topics: Acute Disease; Adult; Aged; Antimanic Agents; Bipolar Disorder; Drug Therapy, Combination; Female; H | 2002 |
Divalproex sodium versus olanzapine in the treatment of acute mania in bipolar disorder: health-related quality of life and medical cost outcomes.
Topics: Acute Disease; Adult; Ambulatory Care; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipol | 2003 |
Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticonvulsants; Antiemetics; Double-Blind Method; Emergency | 2003 |
Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticonvulsants; Antiemetics; Double-Blind Method; Emergency | 2003 |
Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticonvulsants; Antiemetics; Double-Blind Method; Emergency | 2003 |
Intravenous sodium valproate versus prochlorperazine for the emergency department treatment of acute migraine headaches: a prospective, randomized, double-blind trial.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticonvulsants; Antiemetics; Double-Blind Method; Emergency | 2003 |
Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study.
Topics: Acute Disease; Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Doub | 2003 |
The safety and early efficacy of oral-loaded divalproex versus standard-titration divalproex, lithium, olanzapine, and placebo in the treatment of acute mania associated with bipolar disorder.
Topics: Acute Disease; Adolescent; Adult; Aged; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Dia | 2003 |
Single-dose intravenous valproate in acute mania.
Topics: Acute Disease; Adult; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Drug; Female; | 2004 |
Rapid infusion with valproate sodium is well tolerated in patients with epilepsy.
Topics: Acute Disease; Anticonvulsants; Blood Pressure; Cohort Studies; Dose-Response Relationship, Drug; Dr | 2004 |
Topiramate and divalproex in combination with risperidone for acute mania: a randomized open-label study.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Antipsychotic Agents; Basal Ganglia Diseas | 2005 |
Comparison of intravenous valproate with intravenous lysine-acetylsalicylic acid in acute migraine attacks.
Topics: Acute Disease; Analgesics; Aspirin; Double-Blind Method; GABA Agents; Humans; Infusions, Intravenous | 2005 |
[Evaluation of therapeutic project on acute tetramethylene disulphotetramine poisoning and effect on intelligence in children].
Topics: Acute Disease; Adolescent; Adult; Anticonvulsants; Antidotes; Bridged-Ring Compounds; Child; Female; | 2005 |
Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid.
Topics: Acute Disease; Aged; Female; Humans; Leukemia, Myeloid; Male; Middle Aged; Myelodysplastic Syndromes | 2005 |
Service utilization and costs of olanzapine versus divalproex treatment for acute mania: results from a randomized, 47-week clinical trial.
Topics: Acute Disease; Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Cos | 2005 |
Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell | 2005 |
The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemot | 2006 |
Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder.
Topics: Acute Disease; Anticonvulsants; Bipolar Disorder; Drug Administration Schedule; Drug Therapy, Combin | 2005 |
A randomized, placebo-controlled, multicenter study of divalproex sodium extended release in the treatment of acute mania.
Topics: Acute Disease; Adolescent; Adult; Aged; Anticonvulsants; Bipolar Disorder; Delayed-Action Preparatio | 2006 |
Lack of efficacy and potential aggravation of myoclonus with lamotrigine in Unverricht-Lundborg disease.
Topics: Acute Disease; Adult; Age of Onset; Anticonvulsants; Dose-Response Relationship, Drug; Drug Therapy, | 2006 |
Safety and efficacy of intravenous sodium valproate in the treatment of acute migraine.
Topics: Acute Disease; Adult; Anticonvulsants; Female; Humans; Injections, Intravenous; Middle Aged; Migrain | 2007 |
Facial emotion processing in acutely ill and euthymic patients with pediatric bipolar disorder.
Topics: Acute Disease; Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Drug Therapy, Combination; | 2007 |
Relationship of open acute mania treatment to blinded maintenance outcome in bipolar I disorder.
Topics: Acute Disease; Adult; Anticonvulsants; Bipolar Disorder; Clinical Trials as Topic; Double-Blind Meth | 2008 |
Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study.
Topics: Acute Disease; Adult; Anticonvulsants; Anxiety Disorders; Azerbaijan; Diagnostic and Statistical Man | 2008 |
Divalproex in the treatment of acute bipolar depression: a preliminary double-blind, randomized, placebo-controlled pilot study.
Topics: Acute Disease; Adult; Antimanic Agents; Bipolar Disorder; Delayed-Action Preparations; Double-Blind | 2007 |
Switching from other agents to extended-release carbamazepine in acute mania.
Topics: Acute Disease; Adult; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Carbamazepine; Delayed-Ac | 2008 |
Comparative study of ethosuximide and sodium valproate in the treatment of typical absence seizures (petit mal).
Topics: Acute Disease; Adolescent; Adult; Child; Child, Preschool; Clinical Trials as Topic; Epilepsy, Absen | 1982 |
The efficacy and safety of divalproex sodium in the treatment of acute mania in adolescents and young adults: an open clinical trial.
Topics: Acute Disease; Adolescent; Adult; Arousal; Bipolar Disorder; Dose-Response Relationship, Drug; Drug | 1995 |
Valproate in the treatment of acute bipolar affective episodes complicated by substance abuse: a pilot study.
Topics: Acute Disease; Adult; Bipolar Disorder; Comorbidity; Diagnosis, Dual (Psychiatry); Female; Follow-Up | 1995 |
Sodium valproate for acute migraine attacks.
Topics: Acute Disease; Adult; Female; Humans; Male; Middle Aged; Migraine Disorders; Valproic Acid | 1994 |
Valproate oral loading in the treatment of acute mania.
Topics: Acute Disease; Administration, Oral; Adult; Bipolar Disorder; Drug Therapy, Combination; Female; Hos | 1993 |
Divalproex sodium treatment in late adolescent and young adult acute mania.
Topics: Acute Disease; Adolescent; Adult; Bipolar Disorder; Female; Humans; Male; Psychiatric Status Rating | 1993 |
A randomized comparison of divalproex oral loading versus haloperidol in the initial treatment of acute psychotic mania.
Topics: Acute Disease; Administration, Oral; Adult; Basal Ganglia Diseases; Bipolar Disorder; Haloperidol; H | 1996 |
Relation of serum valproate concentration to response in mania.
Topics: Acute Disease; Adult; Bipolar Disorder; Dose-Response Relationship, Drug; Double-Blind Method; Drug | 1996 |
Risperidone in the treatment of mania.
Topics: Acute Disease; Adult; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Confidence Intervals; D | 1996 |
Differential effect of number of previous episodes of affective disorder on response to lithium or divalproex in acute mania.
Topics: Acute Disease; Antimanic Agents; Bipolar Disorder; Double-Blind Method; Humans; Lithium; Placebos; R | 1999 |
A history of substance abuse complicates remission from acute mania in bipolar disorder.
Topics: Acute Disease; Adult; Anticonvulsants; Antipsychotic Agents; Bipolar Disorder; Carbamazepine; Comorb | 1999 |
Tiagabine appears not to be efficacious in the treatment of acute mania.
Topics: Acute Disease; Adult; Anticonvulsants; Bipolar Disorder; Drug Therapy, Combination; Female; GABA Ant | 1999 |
Safety and tolerability of oral loading divalproex sodium in acutely manic bipolar patients.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Bipolar Disorder; Double-Blind Method; Drug | 1999 |
Valproate as an adjunct to neuroleptic medication for the treatment of acute episodes of mania: a prospective, randomized, double-blind, placebo-controlled, multicenter study. European Valproate Mania Study Group.
Topics: Acute Disease; Administration, Oral; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder | 2000 |
Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Chronic Disease; Double-Blind Method; Drug Therapy, Comb | 2000 |
Effect size of lithium, divalproex sodium, and carbamazepine in children and adolescents with bipolar disorder.
Topics: Acute Disease; Adolescent; Age Factors; Antimanic Agents; Bipolar Disorder; Carbamazepine; Child; Do | 2000 |
Intravenous valproate sodium (depacon) aborts migraine rapidly: a preliminary report.
Topics: Acute Disease; Adolescent; Adult; Female; GABA Agents; Humans; Infusions, Intravenous; Male; Middle | 2000 |
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.
Topics: Acute Disease; Adult; Antimanic Agents; Benzodiazepines; Bipolar Disorder; Double-Blind Method; Drug | 2002 |
The evolving role of topiramate among other mood stabilizers in the management of bipolar disorder.
Topics: Acetates; Acute Disease; Amines; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; | 2001 |
Olanzapine versus divalproex in the treatment of acute mania.
Topics: Acute Disease; Adult; Anticonvulsants; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Doub | 2002 |
Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety.
Topics: Acute Disease; Adolescent; Adult; Aged; Antimanic Agents; Antiparkinson Agents; Antipsychotic Agents | 2002 |
Correlates of antimanic response to valproate.
Topics: Acute Disease; Adult; Bipolar Disorder; Double-Blind Method; Female; Humans; Male; Middle Aged; Psyc | 1991 |
Valproate in the treatment of acute mania. A placebo-controlled study.
Topics: Acute Disease; Adolescent; Adult; Aged; Bipolar Disorder; Double-Blind Method; Drug Administration S | 1991 |
Valproate use in acute mania and bipolar disorder: an international perspective.
Topics: Acute Disease; Bipolar Disorder; Clinical Trials as Topic; Europe; Humans; Valproic Acid | 1989 |
140 other studies available for valproic acid and Acute Disease
| Article | Year |
|---|---|
Valproate Induced Acute Pancreatitis - A Unique Case Report.
Topics: Acute Disease; Adolescent; Child; Humans; Pancreatitis; Seizures; Valproic Acid | 2022 |
Acute pancreatitis during valproic acid administration in a patient with vascular dementia, epileptic seizures, and psychiatric symptoms: a case report.
Topics: Acute Disease; Aged; Amylases; Anticonvulsants; Dementia, Vascular; Epilepsy; Humans; Male; Pancreat | 2023 |
Bilateral acute angle closure as presenting feature of Drug Rash with Eosinophilia and Systemic Symptoms (DRESS).
Topics: Acute Disease; Adult; Anterior Eye Segment; Anticonvulsants; Carbamazepine; Drug Hypersensitivity Sy | 2019 |
Long-term safety, tolerability, and efficacy of magnesium valproate versus sodium valproate in acute seizures.
Topics: Acute Disease; Adult; Aged; Anticonvulsants; Female; Humans; Male; Middle Aged; Seizures; Valproic A | 2020 |
Antiepileptic drugs for acute encephalitic patients presented with seizure.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anticonvulsants; Female; Humans; Levetira | 2020 |
Valproic acid for myoclonic epilepsy in POLG1 carriers can be fatal.
Topics: Acute Disease; Anticonvulsants; Child; Diffuse Cerebral Sclerosis of Schilder; DNA Polymerase gamma; | 2021 |
Bilateral subacute lacrimal gland enlargement mimicking dacryoadenitis in a 7-year-old boy: a rare adverse effect of valproic acid (sodium valproate).
Topics: Acute Disease; Anticonvulsants; Child; Dacryocystitis; Diagnosis, Differential; Drug Substitution; E | 2017 |
Valproic acid attenuates the risk of acute respiratory failure in patients with subarachnoid hemorrhage.
Topics: Acute Disease; Adult; Aged; Anti-Inflammatory Agents; Databases, Factual; Female; Humans; Incidence; | 2018 |
Anabolic steroid abuse: what shall it profit a man to gain muscle and suffer the loss of his brain?
Topics: Acute Disease; Adult; Anabolic Agents; Heparin; Humans; Magnetic Resonance Imaging; Male; Nandrolone | 2017 |
Acute Pancreatitis Associated with Valproate Treatment.
Topics: Acute Disease; Antimanic Agents; Chronic Disease; Humans; Pancreatitis; Valproic Acid | 2018 |
Acute Severe Pancreatitis: A Dreadful Complication of Sodium Valproate.
Topics: Abdominal Pain; Acute Disease; Child; Fever; Humans; Male; Pancreatitis; Tachypnea; Valproic Acid | 2019 |
Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus.
Topics: Acute Disease; Amides; Animals; Anticonvulsants; Disease Models, Animal; Guinea Pigs; Humans; Rats; | 2013 |
Bipolar disorder - from endophenotypes to treatment.
Topics: Acute Disease; Adult; Bipolar Disorder; Depressive Disorder, Major; Endophenotypes; Female; Humans; | 2013 |
Development of acute pancreatitis caused by sodium valproate in a patient with bipolar disorder on hemodialysis for chronic renal failure: a case report.
Topics: Abdominal Pain; Acute Disease; Anticonvulsants; Bipolar Disorder; Humans; Japan; Kidney Failure, Chr | 2014 |
Valproic acid-induced pancreatitis in a 15-year-old boy with juvenile myoclonic epilepsy.
Topics: Acute Disease; Adolescent; Anticonvulsants; Estonia; Humans; Male; Myoclonic Epilepsy, Juvenile; Pan | 2013 |
Intravenous Sodium Valproate for Acute Pediatric Headache.
Topics: Acute Disease; Administration, Intravenous; Adolescent; Child; Emergency Service, Hospital; Enzyme I | 2015 |
Psychopharmacological treatment of 1650 in-patients with acute mania-data from the AMSP study.
Topics: Acute Disease; Adult; Anticonvulsants; Antidepressive Agents; Antipsychotic Agents; Benzodiazepines; | 2016 |
The effects of acute and preventive migraine therapies in a mouse model of chronic migraine.
Topics: Acute Disease; Amiloride; Animals; Anticonvulsants; Disease Models, Animal; Drug Evaluation, Preclin | 2016 |
Valproic acid-mediated myocardial protection of acute hemorrhagic rat via the BCL-2 pathway.
Topics: Acute Disease; Animals; Blotting, Western; Cell Hypoxia; Cells, Cultured; Disease Models, Animal; En | 2016 |
[Acute valproic acid overdose causing only somnolence and stagger despite the extreme hyperammonemia: A case report].
Topics: Acute Disease; Adult; Anticonvulsants; Disorders of Excessive Somnolence; Drug Overdose; Female; Hum | 2016 |
A confusing case of confusion. Acute porphyrias.
Topics: Acidosis, Lactic; Acute Disease; Anticonvulsants; Brain; Confusion; Diagnosis, Differential; Diet, R | 2008 |
Mood stabilizer loading versus titration in acute mania: audit of clinical practice.
Topics: Acute Disease; Adolescent; Adult; Antimanic Agents; Bipolar Disorder; Dose-Response Relationship, Dr | 2008 |
Histone deacetylase inhibitors induce a very broad, pleiotropic anticancer drug resistance phenotype in acute myeloid leukemia cells by modulation of multiple ABC transporter genes.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; ATP-Binding Cassette Transporters; Biological Trans | 2009 |
Diagnostic exercise: sudden death in a mouse with experimentally induced acute myeloid leukemia.
Topics: Acute Disease; Animals; Antineoplastic Agents; Death, Sudden; Disease Models, Animal; Female; Leukem | 2009 |
Acute pancreatitis associated to the use of valproic acid.
Topics: Acute Disease; Child; Epilepsy; Female; Humans; Pancreatitis; Valproic Acid | 2009 |
Acute valproic acid overdose: enhance elimination with multiple-doses activated charcoal.
Topics: Acidosis; Acute Disease; Adult; Antidotes; Charcoal; Drug Overdose; Female; Glasgow Coma Scale; Huma | 2009 |
Divalproex extended-release in acute bipolar II depression.
Topics: Acute Disease; Adult; Anticonvulsants; Bipolar Disorder; Delayed-Action Preparations; Dose-Response | 2010 |
[Continuous venovenous haemodiafiltration as a solution for acute intoxication with sodium valproate].
Topics: Acute Disease; Antimanic Agents; Female; Hemodiafiltration; Humans; Middle Aged; Poisoning; Valproic | 2010 |
Incidence, severity, and etiology of drug-induced acute pancreatitis.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Azathioprine; Child; Child, Preschool; Cr | 2010 |
Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia.
Topics: Acute Disease; Aged; Aged, 80 and over; Amino Acid Sequence; Antigens, Neoplasm; Antineoplastic Comb | 2010 |
Efficacy of olanzapine and sodium valproate given alone or as add-on therapy in acute mania. A comparative study.
Topics: Acute Disease; Adult; Aged; Benzodiazepines; Bipolar Disorder; Drug Therapy, Combination; Female; Hu | 2010 |
[Psychotic disorder revealing epilepsy linked to a dysembryoma of the left hippocampus].
Topics: Acute Disease; Adult; Anticonvulsants; Antipsychotic Agents; Diagnosis, Differential; Electroencepha | 2011 |
Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Female; Hist | 2010 |
Molecular adsorbent recycling system therapy in the treatment of acute valproic acid intoxication.
Topics: Acute Disease; Adult; Antimanic Agents; Charcoal; Drug Overdose; Fluid Therapy; Hemoperfusion; Hepat | 2010 |
Novel characterization of drug-associated pancreatitis in children.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Child; Child, Preschool; Comorbidity; Crohn Dise | 2011 |
Acute chorea caused by valproate in an elderly.
Topics: Acute Disease; Aged, 80 and over; Anticonvulsants; Chorea; Dose-Response Relationship, Drug; Female; | 2011 |
A case of acute valproic acid poisoning treated successfully with L-carnitine.
Topics: Acute Disease; Adult; Anticonvulsants; Carnitine; Epilepsies, Partial; Humans; Male; Valproic Acid; | 2012 |
Acute overdose of enteric-coated valproic acid and olanzapine: unusual presentation and delayed toxicity.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzodiazepines; Drug Overdose; Female; Humans; Olanzapi | 2012 |
Valproate in acute mania: is our practice evidence based?
Topics: Acute Disease; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Chemistry, Pharmaceu | 2012 |
Synergistic/additive interaction of valproic acid with bortezomib on proliferation and apoptosis of acute myeloid leukemia cells.
Topics: Acute Disease; Apoptosis; Blotting, Western; Boronic Acids; Bortezomib; Cell Proliferation; Cell Sur | 2012 |
[Acute childhood pancreatitis caused by valproate].
Topics: Acute Disease; Adolescent; Anticonvulsants; Female; Humans; Pancreatitis; Valproic Acid | 2009 |
Acute pancreatitis coincident with valproate use: a critical review.
Topics: Acute Disease; Adolescent; Adult; Amylases; Anticonvulsants; Child; Child, Preschool; Controlled Cli | 2002 |
Favorable outcome of epileptic blindness in children.
Topics: Acute Disease; Adolescent; Anticonvulsants; Blindness, Cortical; Carbamazepine; Child; Electroenceph | 2003 |
Acute akinetic crisis with marked cognitive impairment due to Valproate treatment.
Topics: Acute Disease; Antimanic Agents; Cognition Disorders; Female; Humans; Hypokinesia; Middle Aged; Valp | 2003 |
Safety and efficacy of intravenous valproate in pediatric status epilepticus and acute repetitive seizures.
Topics: Acute Disease; Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Dru | 2003 |
Rapid infusion of sodium valproate in acutely ill children.
Topics: Acute Disease; Adolescent; Anticonvulsants; Child; Child, Preschool; Dose-Response Relationship, Dru | 2003 |
[Fast control of manic or mixed episodes. Atypical neuroleptics for bipolar patients].
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical T | 2003 |
[Long-term therapy with intuition].
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clinical T | 2003 |
Detection and quantitation of xenobiotics in biological fluids by 1H NMR spectroscopy.
Topics: Acute Disease; Humans; Hydrogen; Magnetic Resonance Spectroscopy; Paraquat; Poisoning; Salicylates; | 2003 |
Levetiracetam in focal epilepsy and hepatic porphyria: a case report.
Topics: Acute Disease; Adult; Anticonvulsants; Comorbidity; Epilepsies, Partial; Female; Humans; Levetiracet | 2004 |
Valproic acid inhibits proliferation and induces apoptosis in acute myeloid leukemia cells expressing P-gp and MRP1.
Topics: Acute Disease; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; | 2004 |
The difficulties of diagnosing VPA-induced pancreatitis in children with severe motor and intellectual disabilities.
Topics: Acute Disease; Anticonvulsants; Child, Preschool; Epilepsy; Female; Humans; Intellectual Disability; | 2004 |
Psychotic symptoms associated with topiramate: cognitive side effects or worsening of psychosis?
Topics: Acute Disease; Anticonvulsants; Cognition Disorders; Fructose; Humans; Psychiatric Status Rating Sca | 2004 |
Acute psychosis with a mediastinal carcinoma metastasis.
Topics: Acute Disease; Antipsychotic Agents; Benzodiazepines; Humans; Male; Mediastinal Neoplasms; Middle Ag | 2005 |
Acute pancreatitis and diabetic ketoacidosis in non-diabetic person while on treatment with sodium valproate, chlorpromazine and haloperidol.
Topics: Acute Disease; Adult; Antimanic Agents; Bipolar Disorder; Chlorpromazine; Diabetic Ketoacidosis; Dia | 2004 |
Acute seizures due to a probable interaction between valproic acid and meropenem.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Anticonvulsants; Drug Interactions; Epilepsy; Female; H | 2005 |
Acute leukemia associated with valproic acid treatment: a novel mechanism for leukemogenesis?
Topics: Acute Disease; Adult; Anticonvulsants; Chromosome Aberrations; Chromosomes, Human, Pair 7; Chromosom | 2005 |
Telogen effluvium caused by magnesium valproate and lamotrigine.
Topics: Acute Disease; Adolescent; Adult; Alopecia; Anticonvulsants; Epilepsy; Female; Humans; Lamotrigine; | 2005 |
[An acute pancreatitis in a child caused by Na-valproate].
Topics: Acute Disease; Adolescent; Anticonvulsants; Female; Humans; Pancreatitis; Valproic Acid | 2004 |
Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors.
Topics: Acetylation; Acute Disease; Adult; Antigens, CD34; Butyrates; DNA Methylation; Enzyme Inhibitors; Ge | 2005 |
A positron emission tomography study of the effects of treatment with valproate on brain 5-HT2A receptors in acute mania.
Topics: Acute Disease; Adult; Antimanic Agents; Bipolar Disorder; Brain; Contrast Media; Female; Humans; Lit | 2005 |
Inhibition of retinoic acid receptor signaling by Ski in acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Chromosome Deletion; Chromosomes, Human, | 2006 |
Acute encephalopathy after intravenous administration of valproate in non-convulsive status epilepticus.
Topics: Acute Disease; Electroencephalography; Female; Humans; Injections, Intravenous; Middle Aged; Neuroto | 2006 |
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management of patients with bipolar disorder: update 2007.
Topics: Acute Disease; Antidepressive Agents; Antipsychotic Agents; Anxiety Disorders; Benzodiazepines; Bipo | 2006 |
In vivo apoptosis of CD8(+) lymphocytes in acute myeloid leukemia patients: involvement of soluble HLA-I and Fas ligand.
Topics: Acute Disease; Adult; Aged; CD8-Positive T-Lymphocytes; Enzyme Inhibitors; Fas Ligand Protein; Femal | 2007 |
Translocation-positive acute myeloid leukemia associated with valproic acid therapy.
Topics: Acute Disease; Anticonvulsants; Cell Differentiation; Cell Division; Child, Preschool; Chromosomes, | 2008 |
Quetiapine in the treatment of acute mania: target dose for efficacious treatment.
Topics: Acute Disease; Adult; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; | 2007 |
Safety and tolerability of quetiapine in the treatment of acute mania in bipolar disorder.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Double- | 2007 |
Rates of remission/euthymia with quetiapine in combination with lithium/divalproex for the treatment of acute mania.
Topics: Acute Disease; Affect; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; | 2007 |
Quetiapine in the treatment of acute bipolar mania: efficacy across a broad range of symptoms.
Topics: Acute Disease; Antimanic Agents; Antipsychotic Agents; Bipolar Disorder; Dibenzothiazepines; Double- | 2007 |
Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia.
Topics: Acute Disease; Antineoplastic Agents; Apoptosis; Blotting, Western; Cell Differentiation; Cell Line, | 2007 |
Response and remission in adolescent mania: signal detection analyses of the young mania rating scale.
Topics: Acute Disease; Adolescent; Antimanic Agents; Bipolar Disorder; Dibenzothiazepines; Female; Humans; M | 2007 |
Acute seizures in a patient receiving divalproex sodium after starting ertapenem therapy.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Anticonvulsants; beta-Lactams; Dose-Response Relationsh | 2007 |
Dosing of divalproex extended release.
Topics: Acute Disease; Administration, Oral; Antimanic Agents; Bipolar Disorder; Delayed-Action Preparations | 2007 |
Acute hemorrhagic pancreatitis due to the use of valproic acid in a child.
Topics: Acute Disease; Anticonvulsants; Child; Epilepsy, Generalized; Hemorrhage; Humans; Intellectual Disab | 2008 |
Fructose-1,6-bisphosphate has anticonvulsant activity in models of acute seizures in adult rats.
Topics: Acute Disease; Allylamine; Analysis of Variance; Animals; Anticonvulsants; Behavior, Animal; Deoxygl | 2007 |
Trichotillomania in acute Sydenham's chorea.
Topics: Acute Disease; Adolescent; Anticonvulsants; Chorea; Comorbidity; Female; Humans; Penicillin G Benzat | 2007 |
Alternative therapeutic approaches to the treatment of acute phases of endogenous psychoses.
Topics: Acute Disease; Anticonvulsants; Benzodiazepines; Carbamazepine; Humans; Hypnotics and Sedatives; Psy | 1991 |
Histone deacetylase inhibitor treatment downregulates VLA-4 adhesion in hematopoietic stem cells and acute myeloid leukemia blast cells.
Topics: Acute Disease; Bone Marrow Cells; Cell Adhesion; Cell Line, Tumor; Cell Movement; Down-Regulation; D | 2008 |
Risks of valproate in porphyria.
Topics: Acute Disease; Adult; Epilepsy, Temporal Lobe; Female; Humans; Porphyrias; Valproic Acid | 1980 |
Acute liver disease associated with sodium valproate.
Topics: Acute Disease; Adult; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Epilepsy; Fat | 1980 |
Acute intoxication with valproate.
Topics: Acute Disease; Adolescent; Adult; Child, Preschool; Epilepsies, Myoclonic; Female; Humans; Infant; M | 1982 |
Fatal intoxication with sodium valproate.
Topics: Accidents, Home; Acute Disease; Bronchopneumonia; Humans; Infant; Male; Valproic Acid | 1984 |
Serum amylase in patients treated with sodium valproate.
Topics: Acute Disease; Adolescent; Amylases; Child; Child, Preschool; Clinical Enzyme Tests; Female; Humans; | 1982 |
Pancreatitis during sodium valproate treatment.
Topics: Acute Disease; Female; Hemorrhage; Humans; Infant; Pancreatitis; Seizures, Febrile; Valproic Acid | 1983 |
[Treatment of several psychotic states with the combination of valproic acid with diazepam].
Topics: Acute Disease; Adult; Delusions; Diazepam; Drug Therapy, Combination; Female; Hallucinations; Halope | 1984 |
Sodium valproate and acute hepatic failure.
Topics: Acute Disease; Female; Hepatic Encephalopathy; Humans; Infant; Valproic Acid | 1980 |
[Acute pancreatitis during anticonvulsant therapy using sodium valproinate (ergenyl)].
Topics: Acute Disease; Adult; Female; Humans; Pancreatitis; Valproic Acid | 1980 |
[Acute poisoning by sodium valproate].
Topics: Acute Disease; Adolescent; Female; Humans; Respiration Disorders; Valproic Acid | 1981 |
[Acute sodium valproate poisoning].
Topics: Acute Disease; Humans; Valproic Acid | 1982 |
[Fatal hepatic failure and sodium valproate (author's transl)].
Topics: Acute Disease; Adolescent; Chemical and Drug Induced Liver Injury; Female; Humans; Liver; Valproic A | 1982 |
Acute pancreatitis and sodium valproate.
Topics: Acute Disease; Adult; Female; Humans; Kidney Diseases; Pancreatitis; Valproic Acid | 1982 |
[Fatal pancreatitis associated with valproate therapy].
Topics: Acute Disease; Adolescent; Fatal Outcome; Humans; Male; Necrosis; Pancreatitis; Valproic Acid | 1995 |
[Drug-induced pancreatitis: experience of the Swiss Drug Adverse Effects Center (SANZ) 1981-1993].
Topics: Acute Disease; Adolescent; Adult; Aged; Child; Female; Humans; Male; Middle Aged; Pancreatitis; Retr | 1995 |
Lithium: the present and the future.
Topics: Acute Disease; Bipolar Disorder; Carbamazepine; Depressive Disorder; Drug Interactions; Female; Huma | 1995 |
[Acute pancreatitis induced by valproic acid].
Topics: Acute Disease; Adult; Epilepsy, Absence; Humans; Male; Pancreatitis; Valproic Acid | 1994 |
Decreased plasma protein binding of valproate in patients with acute head trauma.
Topics: Acute Disease; Adult; Craniocerebral Trauma; Female; Humans; Male; Middle Aged; Protein Binding; Ser | 1994 |
[A case of acute intoxication with massive overdosage of slow-release sodium valproate tablets].
Topics: Acute Disease; Adolescent; Adult; Consciousness Disorders; Delayed-Action Preparations; Humans; Male | 1994 |
Valproate-associated acute pancreatitis in a child with neuronal ceroid lipofuscinosis.
Topics: Acute Disease; Child; Female; Humans; Liver; Neuronal Ceroid-Lipofuscinoses; Pancreatitis; Seizures; | 1994 |
Valproate as a loading treatment in acute mania.
Topics: Acute Disease; Adult; Bipolar Disorder; Female; Humans; Male; Middle Aged; Psychotic Disorders; Valp | 1993 |
A pharmacoeconomic model of divalproex vs. lithium in the acute and prophylactic treatment of bipolar I disorder.
Topics: Acute Disease; Ambulatory Care; Bipolar Disorder; Costs and Cost Analysis; Decision Support Techniqu | 1996 |
[Acidosis and hyperlactatemia in acute sodium valproate poisoning].
Topics: Acidosis; Acute Disease; Adult; Female; Humans; Intensive Care Units; Lactates; Male; Retrospective | 1997 |
Association between mood-stabilizing medication and mental health resource use in the management of acute mania.
Topics: Acute Disease; Adult; Aged; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Drug | 1997 |
Is divalproex a cost-effective alternative in the acute and prophylactic treatment of bipolar I disorder?
Topics: Acute Disease; Bipolar Disorder; Cost-Benefit Analysis; Drug Costs; Health Care Costs; Hospitalizati | 1997 |
Successful treatment by direct hemoperfusion of coma possibly resulting from mitochondrial dysfunction in acute valproate intoxication.
Topics: Acute Disease; Adult; Carnitine; Charcoal; Coma; Drug Overdose; Female; Glasgow Coma Scale; Hemoperf | 1997 |
Tolerability of oral loading of divalproex sodium in the treatment of acute mania.
Topics: Acute Disease; Administration, Oral; Adult; Aged; Antimanic Agents; Bipolar Disorder; Dose-Response | 1998 |
Acute valproate ingestion induces symptomatic methemoglobinemia.
Topics: Acute Disease; Antidotes; Charcoal; Child, Preschool; Female; Humans; Methemoglobinemia; Methylene B | 1998 |
On the toxicity of valproic-acid.
Topics: Acute Disease; Adult; Anticonvulsants; Epilepsy, Tonic-Clonic; Humans; Kidney Failure, Chronic; Male | 1999 |
Mania onset while using dehydroepiandrosterone.
Topics: Acute Disease; Bipolar Disorder; Dehydroepiandrosterone; Drug Therapy, Combination; Haloperidol; Hum | 1999 |
Intravenous valproate loading in acutely manic and depressed bipolar I patients.
Topics: Acute Disease; Administration, Oral; Adult; Antimanic Agents; Bipolar Disorder; Dose-Response Relati | 1999 |
Recurrent acute pancreatitis associated with valproic acid use for mood stabilization.
Topics: Acute Disease; Adult; Antimanic Agents; Humans; Male; Pancreatitis; Schizophrenia, Paranoid; Valproi | 1999 |
Paradoxic reaction to lamotrigine in a child with benign focal epilepsy of childhood with centrotemporal spikes.
Topics: Acute Disease; Anticonvulsants; Carbamazepine; Child; Electroencephalography; Epilepsy, Absence; Epi | 1999 |
Fatality from hepatitis A in a child taking valproate.
Topics: Acute Disease; Anticonvulsants; Child; Epilepsy, Complex Partial; Fatal Outcome; Hepatitis A; Hepati | 2000 |
Low-dose lithium augmentation of divalproex in geriatric mania.
Topics: Acute Disease; Aged; Antimanic Agents; Bipolar Disorder; Cognition Disorders; Dose-Response Relation | 2000 |
Parenteral valproate for control of acute mania.
Topics: Acute Disease; Aged; Aged, 80 and over; Bipolar Disorder; Female; Humans; Infusions, Intravenous; Tr | 2000 |
Agitated symptom response to divalproex following acute brain injury.
Topics: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Antimanic Agents; Brain Injuries; Cohort | 2000 |
Nonconvulsive status epilepticus causing acute confusion.
Topics: Acute Disease; Aged; Anticonvulsants; Confusion; Diazepam; Epilepsy, Generalized; Fatal Outcome; Fem | 2000 |
Use of intravenous valproate sodium in status migraine.
Topics: Acute Disease; Adult; Female; Humans; Infusions, Intravenous; Migraine Disorders; Nausea; Pain, Intr | 2000 |
Pharmacologic loading in the treatment of acute mania.
Topics: Acute Disease; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Carbamazepine; Dose-Response Rel | 2000 |
Absence seizures aggravated by valproic acid.
Topics: Acute Disease; Anticonvulsants; Child; Epilepsy, Absence; Female; Follow-Up Studies; Humans; Male; S | 2001 |
Does EEG predict response to valproate versus lithium in patients with mania?
Topics: Acute Disease; Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Brain; Electroencephalogr | 2001 |
[Fatal necro-hemorrhagic pancreatitis related to sodium valproate: case report].
Topics: Acute Disease; Anticonvulsants; Child; Epilepsy; Fatal Outcome; Humans; Male; Necrosis; Pancreatitis | 2001 |
Valproic acid triggers acute rhabdomyolysis in a patient with carnitine palmitoyltransferase type II deficiency.
Topics: Acetylcarnitine; Acute Disease; Antimanic Agents; Bipolar Disorder; Carnitine O-Palmitoyltransferase | 2001 |
Corticosteroid-induced acute mania during a cluster headache episode.
Topics: Acute Disease; Adolescent; Age of Onset; Antimanic Agents; Bipolar Disorder; Cluster Headache; Gluco | 2001 |
Pancreatitis associated with valproic acid therapy.
Topics: Acute Disease; Child; Epilepsy, Absence; Humans; Male; Pancreatitis; Valproic Acid | 1979 |
Acute intoxication with sodium valproate.
Topics: Acute Disease; Adolescent; Adult; Brain Diseases; Epilepsy; Female; Humans; Male; Valproic Acid | 1979 |
[Ultrastructural changes of murine cerebellum after anticonvulsant administration. I. Acute intoxication (author's transl)].
Topics: Acute Disease; Animals; Anticonvulsants; Cerebellum; Mice; Phenytoin; Primidone; Valproic Acid | 1977 |
Acute hepatic failure associated with the use of sodium valproate.
Topics: Acute Disease; Chemical and Drug Induced Liver Injury; Child; Child, Preschool; Epilepsy; Humans; Li | 1979 |
[An adult case of Reye like syndrome and acute pancreatitis associated with sodium valproate].
Topics: Acute Disease; Biopsy; Humans; Liver; Male; Middle Aged; Pancreatitis; Reye Syndrome; Valproic Acid | 1992 |
Algorithm for patient management of acute manic states: lithium, valproate, or carbamazepine?
Topics: Acute Disease; Algorithms; Bipolar Disorder; Carbamazepine; Humans; Lithium; Valproic Acid | 1992 |
Acute sodium valproate intoxication: occurrence of renal failure and treatment with haemoperfusion-haemodialysis.
Topics: Acute Disease; Acute Kidney Injury; Drug Overdose; Female; Hemoperfusion; Humans; Infant; Renal Dial | 1990 |
Effectiveness of sodium valproate in the treatment of Sydenham's chorea.
Topics: Acute Disease; Adolescent; Child; Child, Preschool; Chorea; Female; Humans; Male; Recurrence; Rheuma | 1990 |
Acute liver failure in a patient with hepatitis A infection on sodium valproate therapy.
Topics: Acute Disease; Adolescent; Chemical and Drug Induced Liver Injury; Hepatitis A; Hepatovirus; Humans; | 1990 |
Acute psychosis with carbamazepine and sodium valproate.
Topics: Acute Disease; Adult; Carbamazepine; Drug Interactions; Drug Therapy, Combination; Epilepsy, Tempora | 1989 |
Sodium valproate, pregnancy, and infantile fatal liver failure.
Topics: Acute Disease; Chemical and Drug Induced Liver Injury; Epilepsy; Female; Humans; Infant; Infant, New | 1987 |
Hemorrhagic pancreatitis in a young child following valproic acid therapy. Clinical and ultrasonic assessment.
Topics: Acute Disease; Child, Preschool; Hemorrhage; Humans; Male; Pancreatitis; Seizures; Ultrasonography; | 1987 |
[Prevention of arrhythmias and cardiac fibrillation in acute ischemia and reperfusion by using a factor causing GABA accumulation in the brain].
Topics: Acute Disease; Animals; Arrhythmias, Cardiac; Brain; Coronary Disease; Drug Evaluation, Preclinical; | 1987 |
[Acute valproate poisoning].
Topics: Acute Disease; Adolescent; Brain; Humans; Kidney; Liver; Male; Renal Dialysis; Valproic Acid | 1987 |
[Acute drug-induced pancreatitis].
Topics: Acute Disease; Asparaginase; Azathioprine; Chlorothiazide; Drug-Related Side Effects and Adverse Rea | 1985 |
[A clinico-biochemical study of acute encephalopathy in patients treated with Ca-hopantenate].
Topics: Acute Disease; Adolescent; Adult; Age Factors; Blood Chemical Analysis; Brain Diseases; Child; Child | 1985 |